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Chapter 1: Introduction and review of the literature 
1.1 Introduction 
 
Tuberculous meningitis (TBM) is a common cause of meningitis in adults in 
South Africa (1-3), second only to cryptococcal meningitis in studies of 
microbiologically confirmed meningitis, and accounting for 28% of cases in 
one (1). Conventional diagnostic tests for TBM are, however, relatively 
insensitive, and the true incidence is likely to be underreported. When both 
microbiological and clinical diagnostic criteria (4) are used in the same setting, 
the incidence of TBM rose to 57% (3), emerging as the most common cause 
of meningitis in adults in a district level hospital in the Western Cape. In the 
setting of high human immunodeficiency virus (HIV) and tuberculosis (TB) 
prevalence, approximately 88% of patients with definite or probable TBM are 
co-infected with HIV (3, 5) and six-month mortality in this group approaches 
50% (3). Survivors may be left with long-term disability secondary to 
hydrocephalus, cranial neuropathies, seizures and strokes (6).  
 
1.2 Cognitive impairment associated with TBM 
The impact of TBM on cognition is not clear. A few long-term follow-up studies 
of childhood TBM patients have been carried out in South Africa (7-9). The 
first study from 1997 assessed 19 children at a median follow-up period of 
three years after TBM diagnosis (7). The Herbst test, a culturally appropriate 
developmental assessment tool developed in South Africa (10), was used for 
cognitive testing. The Herbst test assesses 10 aspects of neurodevelopment, 
including concepts of direction, form, colour and number, analysis and 
synthesis, and picture perception. In this study by Schoeman et al. cognitive 
development was scored and expressed as percentages of those expected 
for normal children of similar age and background. Median cognitive 
development in the children with TBM was 66.9% (95% CI 59.1 - 73.2). The 
degree of impairment was similar for all 10 cognitive functions tested, ranging 
from 61.8% to 70.4%. 
 
 2 
The second study described a paediatric cohort of 76 children who were 
followed up at a median period of 6.5 years after TBM diagnosis and used 
intelligence quotient (IQ) testing as a measure of cognition (8). Detailed IQ 
testing, using the Weschler Intelligence Scale for Children, found 
performances suggestive of cognitive impairment in 80% of children; and in 
the majority of these children it was considered likely to be severe enough to 
affect scholastic performance. Interestingly, poor scholastic performance was 
the presenting complaint from only 7% of parents, whereas 22% voiced 
concern about their children’s behaviour, which was in fact the most common 
presenting complaint.  
 
A third retrospective cohort study was performed, spanning 20 years of 
paediatric TBM in the Western Cape (9). Five hundred and fifty-four children 
were followed up at six months after TB treatment and IQ testing was 
performed using the Bayley test, Griffiths test, or Junior South African 
Individual Scale, depending on the age of the child. Patients were grouped as 
“normal” (IQ: > 80), “mild intellectual impairment” (IQ: 50–80), or “severe 
intellectual impairment” (IQ: < 50). In this large study, it was found that 77% of 
children had IQ scores suggestive of cognitive impairment. This cognitive 
impairment was mild in 58% and severe in 19% of children.  
 
Data regarding neuropsychological outcomes after TBM in adults are scarce 
and there is a dearth of published information. A retrospective folder review 
from Auckland City hospital in New Zealand reported cognitive impairment to 
be present in 12% of adult TBM patients who completed TBM treatment at a 
median follow-up period of 18 months (range 1–197 months), but it is unclear 
how cognition was assessed (11). In two cohort studies from India, patients 
were evaluated at six months (12) and one year (13) after TBM diagnosis, 
respectively, using the Mini Mental State Exam (MMSE) (14). Cut-off MMSE 
scores were applied, ranging from 22 to 29, depending on years of education. 
Approximately half of these patients (54% and 55% respectively) were then 
found to be impaired.  
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More recently, the effect of TBM on long-term cognition was studied by Lin et 
al. HIV negative adults with previous TBM underwent Diffusion Tensor 
Imaging (DTI) (15). Nineteen TBM patients were tested at a median of 81 
months post-TBM diagnosis and compared with 32 healthy controls. TBM 
patients performed significantly worse than controls on tests of executive 
function (Digit symbol coding, similarity and picture arrangement from the 
WAIS-III) and visuo-construction function (Picture Complete and block design, 
also from the WAIS-III). Worse neuropsychological performance directly 
correlated with poorer parameters on DTI indices with changes of white 
matter integrity in the anterior cingulate gyrus, the parahippocampal gyrus and 
globus pallidus. A further study by the same group used Diffeomorphic 
Anatomical Registration Through Exponentiated Lie Algebra (DARTEL) voxel-
based morphometry (VBM) to assess the integrity of grey matter in these 
same TBM patients (16). Patients were assessed cognitively using the full 
scale IQ measure from the Chinese version of the WAIS-III. Patients with 
TBM performed significantly poorer on the digit symbol, similarities, block 
design, matrix reasoning, and letter-number sequencing subtests of the WAIS 
compared to healthy adults. These TBM patients were therefore impaired on 
the indices of verbal comprehension, perceptual organisation (non-verbal 
reasoning and structuring of a visual scene), and working memory. These 
changes correlated with smaller grey matter volumes in the right thalamus, 
right superior temporal gyrus, right precuneus, right middle temporal gyrus, 
left putamen, right caudate nucleus, and right middle temporal gyrus. Overall 
this study suggested cortical as well as subcortical (deep grey matter) 
involvement in TBM. 
 
The pathogenesis of cognitive impairment in TBM is unclear and is probably 
multifactorial. Important mechanisms are likely to be secondary vascular 
disease as well as hydrocephalus. Encephalitis may result when the basal 
inflammatory process extends into the parenchyma (17).  
 
Small and medium vessel vasculitis is prominent in the pathology of TBM, and 
may result in ischaemia or infarction, particularly in the territory of the 
perforating branches of the middle cerebral artery (18). A focal clinical 
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neurological deficit in TBM can occur in up to 20% of patients (19). However, 
computed tomography (CT) and magnetic resonance imaging (MRI) may 
reveal cerebral infarctions in a larger proportion of patients, up to 35% and 
57% respectively, rates that are similar to autopsy findings of infarction in up 
to 56% of patients (20). Strokes are often unnoticed clinically for many 
reasons: firstly, the patient may already have an altered level of 
consciousness so that new deficits are not recognised; secondly, co-existent 
arachnoiditis with myelo- or polyradiculopathies may confuse the clinical 
picture; and thirdly, the stroke may be in a clinically silent region of the brain. 
Basal ganglia infarctions are the most common and result from involvement of 
the small perforating arteries, specifically the lenticulostriate arteries. A 
“tubercular zone” has been described with infarction involving the head of the 
caudate nucleus, anteromedial thalami and anterior limb and genu of internal 
capsule. Up to 75% of patients with a basal ganglia infarct have an infarct in 
this region (18). 
 
In addition to vascular changes, hydrocephalus secondary to TBM may 
impact on cognition. The development of hydrocephalus is more common in 
children than adults with TBM, with a CT study finding that 12% of adults had 
severe hydrocephalus, contrasting with 87% of children (21). A recent 
American study found that 8.4% of adult patients with TBM required 
ventriculoperitoneal shunting for hydrocephalus (22). The thick inflammatory 
exudate in the subarachnoid space impairs cerebrospinal fluid (CSF) 
drainage, particularly around the basal cisterns, leading to communicating 
hydrocephalus (23). It has been suggested that the presence of 
hydrocephalus may be associated with worse outcomes (death or significant 
disability) at one year and with higher risk of strokes (24). Cognitive outcomes 
in hydrocephalus primarily relate to the underlying etiology, but in paediatric 
studies visuospatial difficulty and motor dysfunction have been found 
regardless of the cause (25). Adults with normal pressure hydrocephalus may 
have impairment in multiple cognitive domains, particularly memory and 
learning; dexterity; reaction time; and executive functions; and it is plausible 
that chronic hydrocephalus post-TBM may cause similar dysfunction (26). 
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1.3 Cognitive impairment associated with HIV 
Approximately 50% of HIV-infected patients will also present with HIV-
associated neurocognitive disorder (HAND) (27) and this will undoubtedly 
impact on the cognitive profile of patients co-infected with HIV and TB. The 
Frascati criteria for HAND defines three subgroups: asymptomatic 
neurocognitive impairment (ANI), which is characterised by mild cognitive 
impairment (scoring between one and two standard deviations [SDs] below 
the mean in at least two cognitive domains) in the absence of functional 
impairment; mild neurocognitive disorder (MND), with a similar level of 
cognitive impairment but additional functional impairment; and HIV-associated 
dementia (HAD), with more severe cognitive impairment (more than two SDs 
below the mean in at least two cognitive domains) with significant functional 
decline (28).  
 
The neurocognitive profile of HAND has evolved as treatment of HIV-infected 
patients improved. In the era before antiretroviral therapy (ART), slowing of 
motor and cognitive processing; impaired fluency; learning; and abstraction 
was found (29, 30). In the modern ART era, more frequent impairment in 
verbal memory (learning) and complex attention has been described (31, 32). 
Additional cortical deficits over and above the subcortical features have been 
suggested, but HAND test batteries have not been designed to test language 
and visuospatial skills sufficiently (31). Because individuals with HIV are now 
living a near normal life span, the effects of aging also need to be considered. 
It has been hypothesised that the increased prevalence of co-existing 
neurodegenerative processes in older individuals add to the risk cognitive 
decline (33). Supporting this theory, a study by Valcour et al. (34) has 
demonstrated the independent risk of HAD relating to apolipoprotein E4 in 
older participants but not in younger participants.  
 
In the developed world in the era of ART, severe forms of HAND (i.e. HAD) 
have become rare, documented in only about two percent of patients (27) 
compared to 10-15% of patients with HAD in the pre-ART era (35). However, 
milder forms of HAND persist and about half of all treated patients with HIV 
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still demonstrate cognitive impairment, as evidenced largely by studies from 
developed countries (27, 36).  
 
However, in developing countries the prevalence of HAD is likely to be higher, 
although varying results have been reported from African countries: 31% of 
HIV-infected patients from Kampala in Uganda were diagnosed with HAD 
(using the Memorial Sloan-Kettering [MSK] severity score) (37), while a 
Malawian study reported lower rates of 3% when applying the Frascati criteria 
(38). In Botswana, the international HIV dementia scale (IHDS) was used with 
a cut-off score of 9.5 to indicate possible HAD, and found that 38% of patients 
were at risk (39). In South Africa, rates of HAD of up to 25% have been 
reported in an ART naive cohort (40).  
 
When one looks at all classes of HAND (and not just HAD) in South Africa, 
the prevalence data varies depending on the cohort studied (e.g. ART usage; 
outpatient or hospital setting) and the testing employed to diagnose or screen 
for HAND (eg. detailed neuropsychological testing, IHDS). Subsequently, the 
incidence of HAND varies widely from 23.5% to 76.5% (40-42). A study 
performed in the Western Cape by Joska et al. using detailed 
neuropsychological testing found a high rate of HAND in 76.5% of ART naïve 
patients attending a primary health care clinic (40). Of these patients with 
HAND, 25% were severely affected with HAD. If this is reflective of the larger 
population of people living with HIV in South Africa, then well over a million 
people may be at risk for HAD (43).  
 
In studies of HAND in South Africa, the prominent domains affected are 
similar to other descriptions: learning, motor processing speed and executive 
functioning (40, 44). This pattern of impairment may be explained by 
neurotoxic effects of HIV, which are most prominent in frontal-subcortical 
structures. The basal ganglia; the caudate in particular (45); as well as the 
frontal neocortex and the white matter tracts connecting these regions, have 
been shown to be affected by HIV (46). Another region shown to be involved, 
using DTI, is the corpus callosum (47). Splenium abnormalities were 
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associated with dementia severity and psychomotor slowing, while genu 
abnormalities were associated with visual memory dysfunction.  
Advancing age (34), lower nadir CD4 lymphocyte count (48), alcohol use (49) 
and lower levels of education (50) are associated with neurocognitive 
impairment.  
 
1.4 Cognitive impairment associated with HIV-associated TBM 
There are no published studies of cognitive outcomes in HIV-associated TBM. 
Based on our review of the literature, similar subcortical structures may be 
affected in both HAND and TBM. This may compound the individual risk of 
cognitive impairment or may worsen the degree thereof. Although additional 
cortical involvement may be seen in HAND in the first world in the ART era, 
this has not been described in South Africa. It has been suggested by the 
small studies referenced above (15, 16), that visuospatial deficits may be 
seen in TBM over and above the subcortical picture. 
 
A pathologic study of alterations of astrocytes and microglia in postmortem 
human brains compared TBM only, HIV only, and TBM and HIV co-infection 
(51). In TBM alone, there is activation of microglia and astrocytes with 
hypertrophy and hyperplasia, aggregating in the subpial zone and around 
granulomas. However, in TBM and HIV co-infection there was a muted glial 
and microglial response. The microglial and astroglial response in the central 
nervous system (CNS) may act two-fold: as a direct effector of infection-
related damage and, on the other hand, as a neuroprotectant. An alteration of 
the immune response in TBM in association with HIV infection was thus 
demonstrated, although the nature of neuronal-astroglial-microglial interaction 
and its impact should be studied further. 
 
Ongoing neural injury in HIV may be driven by chronic inflammation in the 
ART era. This may be facilitated by low-level viral replication in the CNS or 
abnormal immune activation triggered by HIV (46). Alarmingly, this chronic 
inflammation may even persist despite good virologic control and is a possible 
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explanation for the high prevalence of HAND in the ART era (32). Neural 
injury may be exacerbated by cofactors such as substance abuse, co-
infections (e.g., hepatitis C) (52, 53), and aging (33). Based on this evidence, 
one might hypothesise that systemic inflammation, as driven by chronic TB 
infection, may also contribute to worsening neuronal functioning. 
 
There is no direct evidence to confirm or reject the hypothesis that HIV 
worsens the effect of TBM on cognition, as it has not been studied 
systematically. However, the interaction between HIV infection and 
tuberculous meningitis has been studied in Vietnam by Thwaites et al. (54), 
looking at the effect of HIV on clinical presentation, response to treatment, 
and outcome. They found a detrimental effect of HIV infection on survival 
(relative risk of death at nine months from any cause, 2.91 [95% confidence 
interval, 2.14–3.96]). However, there were no significant differences between 
the incidence of severe disability (as defined by scores of 3, 4, or 5 on the 
modified Rankin scale or functional dependance on the “simple questions” 
score) between the HIV-infected and HIV-uninfected survivors after nine 
months of treatment. This finding was confirmed in a recent retrospective 
study in America, where TBM patients with HIV infection were found to not be 
at increased risk of complications (strokes, seizures, hydrocephalus, visual or 
hearing impairment) as compared to patients without HIV infection (22). 
 
1.5 Summary 
HIV is highly prevalent, as is TB. Both of these infectious diseases may lead 
to neuropsychological impairment and it is reasonable to expect that TB and 
HIV together may have compounding effects on cognition. In our setting of 
high HIV/TB co-infection there is a need for a systematic study of cognitive 
performance of HIV-infected TBM patients. We need to identify the risk and 
quantify the burden of this form of disability as a consequence of TBM. The 
impact of cognitive impairment on the daily functioning of these patients may 
have important socio-economic implications.  
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Chapter 2: Aims and hypotheses 
 
2.1 Purpose of the Study 
The purpose of our study is to measure and describe cognitive functioning in 
adult HIV-infected patients with TBM. 
 
2.2 Aims 
2.2.1 Primary aim 
To determine the cognitive outcome of adult patients with HIV-associated 
TBM compared to HIV-infected patients with TB infection outside of the CNS 
compartment (hereafter referred to as extra-CNS TB), at six months after TB 
treatment initiation.  
 
2.2.2 Secondary aims 
1. To assess cognition in conjunction with its impact on daily functioning; 
2. To describe the pattern (neuropsychological profile) of cognitive 
impairment for the two patient groups; and highlight the cognitive 
performance in patients with an impaired global deficit score (GDS); 
3. To identify predictors of poor cognitive outcome; and 
4. To assess the impact on quality of life and employment status  
 in TBM patients at six months after TB treatment initiation. 
 
In order to address these aims, specific hypotheses were drafted.  
 
2.3 Hypotheses 
2.3.1 Primary hypothesis   
HIV-associated TBM patients will have a more severe degree of cognitive 
impairment as measured by the continuous GDS (55) than patients with extra-
CNS TB; and the proportion of patients with cognitive impairment will be 
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larger for TBM patients than extra-CNS TB patients as measured by a GDS of	 
≥ 0.5; at six months after TB treatment initiation. 
 
2.3.2 Secondary hypotheses   
1. The Frascati criteria for HAND (28) incorporate daily functioning into its 
classification of patients, as discussed in Chapter 1. We hypothesise that 
TBM patients will have more functional decline as measured by: the 
Lawton instrumental activities of daily living scale (IADL), modified for 
South Africa (56, 57); the Patient's Assessment of Own Functioning 
Inventory (PAOFI) (58); and the Deterioration Cognitive Observee (DECO) 
(59); as compared to extra-CNS TB patients. This functional decline, 
alongside cognitive impairment, will lead to worse grades of HAND by 
Frascati criteria in TBM patients. 
2. The pattern of neuropsychological impairment in TBM is likely to be of a 
subcortical nature. Similar frontostriatal structures, and the white matter 
tracts connecting these regions, have been implicated in both HIV (33, 46) 
and TBM (12, 18). In TBM patients, there are two possible additional 
manifestations: cortical deficits due to larger arterial strokes (18) and 
visuospatial impairment based on previous studies (15, 16). 
3. The following variables will be associated with worse cognitive outcome at 
six months: 
3.1. In both groups: older age; female gender; lower level of education; 
smoking; alcohol use; the presence of traditional vascular risk factors; 
lower CD4 lymphocyte count at diagnosis; not being on ART at time of 
diagnosis; and shorter duration on ART at six months follow-up. 
Although the presence of strokes is a likely predictor of poorer 
outcome, the observational design of this study does not lend itself to 
standardised neuroimaging and was therefore not included as a 
predictor. 
3.2. In the TBM group: a diagnosis of TBM-immune reconstitution 
inflammatory syndrome (IRIS); and more severe TBM disease grading 
at diagnosis, as defined by Grade II or III on the modified British 
Medical Research Council (BMRC) scales (60). 
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3.3. In the extra-CNS TB group: the presence of disseminated TB as 
opposed to single-site TB.  
4. Patients with TBM will have poorer quality of life (QOL), as assessed by 
the Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form 





Chapter 3: Methods 
 
3.1 Design 
This was a prospective, observational, cohort study. The cohort consisted of 
HIV-infected adults. The exposed group is defined as having TBM and the 
non-exposed group as having extra-CNS TB. The outcome of interest was the 
presence of cognitive impairment at six months after TB diagnosis as 
measured by the GDS (see Figure 3.1).  
 
 
Figure 3.1: Our cohort study design 
 
3.2 Sample size power calculation 
This was a pilot study as there is scant data on cognitive outcomes in adults 
with TBM and no data in HIV-infected adult TBM patients. Based on studies in 
HIV-uninfected adults, Kalita et al. found cognitive impairment as assessed by 
the MMSE in 36/65 (55%) patients at one year follow-up (13). Ranjan et al. 
found similar rates of impairment as assessed by the MMSE at six months 
follow-up: 13/24 (54%) patients were affected (12).  
 
Our sample size estimation was as follows:  This data indicated that the 
probability of the outcome (cognitive impairment) among exposed individuals 





















non-exposed subjects (extra-CNS TB patients), we would be able to detect 
true probabilities of the outcome (cognitive impairment) among cases of 0.254 
or 0.746 with probability (power) = 0.8. The Type I error probability associated 
with this test of the null hypothesis that the outcome rates for case and 
controls are equal is 0.05.  
 
3.3 Ethics 
The study was approved by the University of Cape Town (UCT) Faculty of 
Health Sciences Human Research Ethics Committee (HREC 565/2014) as 
well as the Western Cape Health Research Committee (WC_2014RP4_14 




We recruited patients from three secondary level hospitals in the Cape Town 
Metropolitan district in the Western Cape Province: New Somerset Regional 
Hospital, Khayelitsha District Hospital and Mitchell’s Plain District hospital. 
These hospitals predominantly serve patients with a low income from densely 
populated areas. The majority of patients presenting to these referral centers 
speak isiXhosa as a first language with Afrikaans and English being the home 
language in smaller proportions (63). The Cape Town Metro district accounts 
for approximately 66% of the population of the Western Cape province. 
Migration stream from outlying provinces is a factor in the province’s 
population growth with a total population gain of 94,600 for the period 2006-
2011 (64).  
 
Antenatal HIV-seroprevalence rates in the province are estimated at 18.5% 
(64). The HIV epidemic is currently driving the TB epidemic with more than 
70% of TB patients also living with HIV (65). In 2015 the incidence of TB 
cases in South Africa was 834 per 100 000 population, of which 258 000 were 
HIV-related. This equates to similar rates in the Western Cape in 2010 when 
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the incidence rate of all TB cases was 885 per 100 000, one of the highest 
incidences for all smear positive cases of TB in South Africa (64).  
 
3.5 Recruitment of participants 
3.5.1 Inclusion/exclusion criteria 
Inclusion and exclusion criteria are set out in Table 3.1 and Table 3.2 below. 
 
 
Table 3.1: Inclusion criteria 
Inclusion criteria 
Applicable to both TBM and extra-CNS TB patients 
• Adults (age 18-65 years) 
• HIV-infected 
• Diagnosed with TB in past 10 days 
TBM patients Extra-CNS TB patients 
Definite or probable TBM diagnosis1 Extra-CNS TB based on clinical features 
compatible with TB  
plus at least one of the following: 
1. acid fast bacilli seen on 
microscopy,  
2. Xpert MTB/RIF positivity, 
3. Mycobacterium tuberculosis 
culture positivity,  
4. supportive histological findings,  
5. supportive radiological findings, 
or  
6. based on treating physician’s 
discretion2  
1TBM diagnosis as defined by clinical research criteria (4)  
2This group of patients will be reviewed individually and included based on consensus opinion 
amongst the study team.  
Abbreviations: Extra-CNS TB = Tuberculosis outside of the nervous system; HIV = Human 





Table 3.2: Exclusion criteria 
Exclusion criteria 
Applicable to both TBM and extra-CNS TB patients: 
• Significant CNS disease including previous stroke, previous CNS 
opportunistic infection (e.g. cryptococcal meningitis, neurosyphilis, TBM) 
• Known prior cognitive impairment or dementia as defined by a known 
diagnosis of dementia, or HAND, or a referral to a specialist clinic with a 
concern regarding cognitive impairment  
• Illegal substance use and/or high level drinking or dependance in the 
preceding six months as defined by the Alcohol Use Disorders Identification 
Test (AUDIT, score ≥ 16) (66, 67)  
• Poor socio-economic support that would make return to follow-up 
appointment non-feasible1  
• Multi-drug resistant TB2 
TBM patients Extra-CNS TB patients 
Any other cause for CNS symptoms 
identified after enrollment e.g. 
cryptococcal meningitis, neurosyphilis 
• Symptoms and signs suggestive 
of TBM3  
• Investigations, such as lumbar 
puncture, performed at the 
discretion of the treating 
physician that are suggestive of 
TBM or any other cause of CNS 
disease in addition to extra-CNS 
TB. 
1These included patients who do not have a fixed abode, no telephonic contact details and no 
family member/ friend/carer with telephonic contact details. In such patients we would have been 
unable to perform a telephonic interview at two months and it is very unlikely that these patients 
would have returned for a follow-up visit in six months’ time, hence the reason for their 
exclusion.  
2Patients with MDR TB were excluded as non-standard drug regimes may be a confounder of 
cognitive outcomes.  
3Symptoms include headache, irritability, vomiting (not related to gastro-enteritis), neck 
stiffness, convulsions, focal neurological deficits, and altered consciousness as outlined in 
research criteria (4) 
Abbreviations: CNS = Central nervous system; Extra-CNS TB = Tuberculosis outside of the 
nervous system; HAND = Human immunodeficiency virus-associated neurocognitive disorder; 
HIV = Human immunodeficiency virus; TB = Tuberculosis; TBM = Tuberculous meningitis. 
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3.5.2 Recruitment procedures 
All treating physicians were informed of our study by way of a presentation at 
a local academic meeting where referral of potential patients was invited. 
Further paper advertisements were posted in doctors’ offices in the medical 
wards and casualty departments. Additionally, we accessed the National 
Health Laboratory Services (NHLS) web-based reporting system to identify 
possible TBM cases admitted to either of the three secondary level hospitals 
where our study was conducted, by screening for markedly abnormal CSF 
examinations using previous TBM study criteria (one of the following criteria 
present:  neutrophils > 5 cells x 106/L, lymphocytes> 20 cells x 106/L, protein 
>1 g/L, and glucose <2.2 mmol/L) (3). The medical wards and casualty 
departments were visited twice weekly to screen patient folders for eligible 
patients. Such patients were then approached and invited to participate. 
 
3.5.3 Informed consent 
3.5.3.1 Capacity	  to	  consent	  
The majority of patients with TBM will have an altered level of consciousness. 
This confusional state that results from the meningitic process renders these 
patients unable to give valid informed consent. The legal issues around the 
use of proxy consents in South Africa are unresolved (68, 69). Despite the 
absence of clear law regarding substitute decision-making in research in 
South Africa, both Pope and Roux argue that proxy consent in line with 
Section 7(1) of the Health Act 2003 should be permissible. Such a position is 
in line with the Medical Research Council and the Department of Health (DoH) 
Research Ethics Guidelines, both of which allow for proxy consent to be used 
in research involving people unable to consent. The DoH Ethics Guidelines 
stipulate that proxy consent should only be permissible where research does 
not pose additional risks to research participants, and where consent is 




Our study was primarily observational in nature and did not expose research 
participants to more than minimal risk. We also sought consent from the 
participants before they were discharged from the hospital if they regained 
decisional capacity. If at any time-point participants refused consent, we 
destroyed all data collected.  
 
With regard to determining suitable proxies, we followed Section 7(1) of the 
National Health Act of 2003, that stipulates “a health service may not be 
delivered unless the user is unable to give informed consent and no person is 
mandated or authorised to give such consent, and the consent is given by the 
spouse or partner of the user or, in the absence of such spouse or partner, a 
parent, grandparent, an adult child or a brother or a sister of the user, in the 
specific order as listed”. Therefore, we sought consent from a spouse or 
partner in the first instance, or parent/child/sibling if spouse/partner was not 
available.  
 
In cases where no family member was contactable and given the patient 
didn’t decline assent, we enrolled the patient and continued to seek contact 
with relatives. Furthermore, delayed consent was sought from patients as they 
regained decision-making capacity. 
 
3.5.3.2 Consent	  and	  assent	  forms	  
All consent forms were translated into isiXhosa. We outlined the study 
requirements separately in the informed consent form and incorporated 
checkboxes at the end of the consent form for each separate aspect:   
a) the neurological examination and Case Report Form (CRF); 
b) the two-month telephone call; 
c) the six-month visit for neuropsychological testing. 
 
Using this outline, we could obtain consent for each aspect separately in a 
chronological fashion as it became pertinent to the study.  
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3.6 Research procedures 
3.6.1 Baseline procedures at TB diagnosis 
Following informed consent, suitable patients were enrolled. A medical history 
was taken from patients and/or family. For patients who were disorientated or 
lacked clarity regarding their symptoms, collateral history was taken from 
family members where possible. The medical notes of admitting doctors were 
also reviewed for additional information regarding details of the presenting 
complaint. For patients without family members present, we aimed to obtain a 
history during the time of admission by contacting family members 
telephonically or by personal interview. Patients underwent a neurological 
examination, which allowed determination of the level of consciousness and 
the presence or absence of focal neurological signs by assessing cranial 
nerves, the motor, sensory and cerebellar systems. This allowed grading of 
TBM severity using the modified BMRC grading (60) where patients with 
grade I disease have a Glasgow Coma Scale (GCS) score of 15 with no focal 
neurologic signs; patients with grade II either have a GCS score of 11 to 14, 
or have a GCS score of 15 with focal neurologic signs; and patients with 
grade III have a GCS score of 10 or less, regardless of the presence/absence 
of focal neurological signs. 
 
The following data was documented on a standardised CRF:   
 1. Demographic details (including age, gender, substance use 
 [including completion of the AUDIT questionnaire], level of education, 
 and employment status) 
 2. Medical comorbidities and medication use previously and during 
 hospitalisation e.g. ART and steroid therapy 
 3. History of clinical presentation 
4. A neurological examination including the TBM severity grade using 
the modified BMRC grading (60) 
5. Tests performed as part of routine medical care e.g. CD4 
lymphocyte count, full blood count, electrolytes, cerebrospinal fluid 
findings, radiological investigations, and any additional special 
investigations pertaining to TB and/or HIV.  
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6. Neuroimaging findings (CT and/or MRI if performed) 
 
To minimise loss to follow-up, we recorded multiple phone numbers 
(especially land line telephone numbers) for both patients and for multiple 
contacts at enrolment. We documented addresses for patients and contacts. 
We also documented the patient’s primary health care clinic details so as to 
reach a patient here by liaising with clinic staff. For patients who were re-
admitted following diagnosis, the medical folder was reviewed to document 
hospital outcome. 
 
3.6.2 Two-months follow-up 
At two months following initiation of TB treatment, patients were contacted 
telephonically to enquire regarding compliance with TB drug therapy and 
whether ART had been initiated or is being continued. Patients were also 
asked regarding any serious intercurrent illnesses or additional admission to 
hospital. If so, hospital records were reviewed to ascertain the nature of the 
illness, e.g. an IRIS. 
 
3.6.3 Six-months follow-up 
At six months following TB diagnosis, patients were assessed using a detailed 
validated neuropsychological battery (see Section 3.7 below) as well as 
patient and carer questionnaires (see Section 3.8 below). This face-to-face 
interview took place either at Groote Schuur Hospital or Khayelitsha District 
Hospital in a quiet, private room. All testing for English- and Afrikaans-
speaking patients was performed by the investigator herself following 
neuropsychological training. A research assistant, trained in administration of 
the tests (including practice sessions with non-study participants), performed 




3.6.4 Reimbursement for Participation 
Patients were reimbursed for their time and transport cost to the amount of 
R150 in cash.  
 
3.7 Neuropsychological battery 
The cognitive battery included tests validated in HAND studies in South Africa 
in the past (40, 44); for which normative data (obtained from 103 patients) 
was available; and which had been forward- and back-translated into 
isiXhosa. We also added three tests for which normative data was obtained: 
Judgement of Line Orientation test (JLOT) (70); action fluency (71); and the 
CLOX test (72). These norms were obtained from a local isiXhosa speaking 
population in Khayelitsha, Western Cape, as a nested study within a larger 
norming study (Gouse et al., Human Research Ethics Committee Reference 
number: 596/2014). This study enrolled 114 healthy controls. The battery that 
we performed spans eight cognitive domains with at least two tests per 
domain (see Table 3.3). The neuropsychological battery took approximately 
two hours to administer. Patients were given a tea break halfway through to 




Table 3.3: Cognitive battery listing domains and subtests within each domain  
1Neuropsychological Tests according to 
Domain 
What the test entails 
Motor skills 
Grooved Pegboard Test (73) Timed test consisting of pegboard with 25 holes 
with randomly positioned slots. Pegs with a key 
on one side must be rotated to match the hole 
before they can be inserted. Test of dexterity and 
motor speed; performed with the dominant and 
non-dominant hand once only 
Finger Tapping Test Timed test in which the tip of the thumb must be 
tapped against the tip of each other finger on the 
hand in sequence. This task must be performed 
five times, with the dominant and non-dominant 
hand in turn. 
Memory (learning, recall) 
The Hopkins Verbal Learning Test revised 
(HVLT-R) (74,	  75) 
A list of words is read to the participant. These 
words must be immediately repeated (three trials 
are allowed, with a rereading of the list in 
between). This creates the learning score. The 
words must then be recalled after 20 minutes, 
and also be recognised from a longer list of 
words with other distracter words. These tasks 
create the recall score. 
The Brief Visuospatial Memory Test-revised  
(BVMT-R) (76) 
Participants view 6 geometric figures laid out in a 
2x3 array on a page for 10 seconds. They must 
then reproduce this as closely as possible from 
memory. Three learning attempts are required. 
25 minutes later the test is repeated. At this 
stage the participants are also requested to 
identify the 6 figures from a list of 12 similar 
figures. 
Psychomotor processing speed 
Trail making Test A (TMT A) (77) Timed test in which circled numbers must be 
connected in ascending sequence. 
Color Trail Test I (CTT 1) (78) Timed test in which circled numbers must be 
connected in ascending sequence. (The colour of 
the circled numbers alternates as the numbers 
ascend, but there is only one of each number.) 
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Wechsler Adult Intelligence Scale,  3rd Edition – 
WAIS III (Digit symbol coding and symbol search) 
(79) 
 
In digit symbol coding, the participant is 
presented with digit-symbol pairs. They are then 
subsequently required to write the appropriate 
symbol next to a list of digits, as quickly as 
possible. 
Symbol search requires correctly identifying 
given symbols from a list of similar symbols, 
under time pressure. 
Attention (and working memory) 
Wechsler Memory Scale—III (Digit span) (80) 
 
For the forward digit span, participants are asked 
to repeat a string of numbers which increase in 
length. For the backward digit span participants 
are required to repeat a digit string in the reverse 
order. This digit string also becomes 
progressively longer.  
Wechsler Memory Scale III (Mental control) (80) The participants are required to recite known 
sequences, such as numbers from 1-20, the 
alphabet, days of the week and months of the 
year. With the exception of the alphabet, these 
tasks are then repeated in reverse (i.e. counting 
20-1, days’ order backwards etc). Finally the 
participant needs to say the days of the week 
sequentially, alternating each day with an 
increasing number of 6 added (i.e. 0 Sunday, 6 
Monday, 12 Tuesday etc). All these tasks are 
done under time pressure.  
Mental Alternation Test (MAT) (81) Participants initially count to twenty, then recite 
the alphabet, then do both at the same time, 
alternating numbers and letters in ascending 
sequence. This is done under time pressure. 
Executive Function 
Stroop Color Word Test (SCWT) (82) In this task, the participant is asked to recognise 
colours, then read the names of colours in black 
and white print, before being shown a sheet with 
the names of colours, printed in another colour 
(e.g. RED written in blue ink). Here, they are 
required to say the colour that they see and not 
read the word printed. This test is timed. 
Color Trial Test II (CTT II) (78) Timed test in which circled numbers must be 
connected in ascending sequence, alternating 
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between two different colours of circle. (The 
correct colour must be chosen each time – each 
number appears in both colours). 
Verbal fluency (and executive functioning) 
Category Fluency Test (Animals & 
Fruit/Vegetables) (83) 
Participants must name as many animals (or 
fruits and vegetables) as possible within one 
minute. 
Action Fluency (71) Participants must name as many verbs as 
possible within one minute. They are told: “I 
would like you to tell me as many different things 
as you can think of that people do” 
Visuospatial skills 
Judgement of Line Orientation Test (JLOT) (70) Participants are asked to match two angled lines 
to a set of 11 lines that are arranged in a 
semicircle and separated 18 degrees from each 
other on a multiple choice response card. 
CLOX test (72) Participants are asked to draw a clock displaying 
a certain time (unprompted task, CLOX 1). In the 
second part of this test they observe the 
examiner drawing a similar clock and are asked 
to copy this (copying task, CLOX 2). 
1Partly reproduced with permission from: Cross, HM, Combrinck MI. “HIV-Associated 
Neurocognitive Disorders: Biomarkers and the Response to Antiretroviral Therapy”. MSc, 
University of Cape Town, 2012 (84) 
 
The neuropsychological battery was largely based on strong evidence of a 
subcortical pattern of cognitive impairment in HIV. The predominantly affected 
ability domains include: learning of new information; attention; and speed of 
information processing. Furthermore, the nature of memory deficits in HIV has 
been shown to be due to subcortical retrieval difficulty, rather than 
hippocampal pathology (85). We used a similar ability domain classification as 
proposed in the Frascati classification of HAND (28) and by Carey et al. in 
developing the GDS score (55). In addition to these seven suggested domain 
abilities, we added a visuospatial domain based on the suggestion of 




3.8.1 Patient administered questionnaires 
Questionnaires assessing quality of life, apathy, mood, motor functioning and 
activities of daily living were administered to patients. They were given a 
break prior to this part of the session. These took approximately 30-45 
minutes to administer: 
 
1. The PAOFI (58), assessing the patient’s sense of functional capacity 
validated in populations with cognitive or psychiatric impairment (86, 87). This 
scale has been widely used in South African based studies of HAND (42).  
2. The Q-LES-Q-SF (61). This scale has been used in general psychiatric 
settings (88) as well as South African studies relating to HAND (40, 42).  
3. The modified Rankin Scale (mRS) as a measure of motor outcome. 
This is a well-known measure of motor disability, frequently used in TBM trials 
(60, 89). 
4. Beck’s depression inventory II (BDI II), widely validated in developed 
and developing countries (90, 91). Standard cut-off scores (91) to delineate 
mild (14-19), moderate (20-28) or severe (29-63) depression were applied. 
5. The IADL - modified for South Africa (56, 57).  
 
3.8.2 Carer/ family member administered scales 
The following two scales were completed by a family member or carer (either 
personally if accompanying the patient or by telephonic interview): 
1.      Marin’s Apathy Evaluation Scale - Informant version (AES-I) (92), used 
in the Groote Schuur Hospital Memory clinic and in imaging studies of HIV-
infected patients with HAND in South Africa (93). A cut-off score of 34 or more 
was used to delineate significant apathy as based on norms from a healthy 
population with ages ranging from 20-65 years (94).  
2. The DECO scale, that compares current cognitive functioning with 
status one year prior (59). This observer questionnaire has been used in a 
heterogenous elderly population in South Africa (95) and is also used in the 
Groote Schuur Hospital Memory clinic.  
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We sought participation from family members/carers who fulfilled the following 
inclusion criteria:   
a)   Should have known patient for six months prior to patient presenting with 
TB to ensure premorbid knowledge of patient. 
b)   Should either have lived with patient or have at least had weekly 
interaction (personally or telephonically) with preference given to participants 
living with the patient. 
An exclusion criterion was significant CNS disease in the participant that 
would have rendered him/her unable to recall and/or relay details regarding 
the functioning of the patient (e.g. significant head injury, known diagnosis of 
dementia, known psychiatric disease). 
 
For all participating family members or carers, the patient’s HIV status was not 
disclosed unless the participant volunteered knowledge thereof. Therefore 
references to HIV were omitted in the informed consent form for carers. 
 
3.9 Privacy and Confidentiality 
Study data was and will continue to be stored in a locked cabinet in a limited 
access office in the Neurology Department at Groote Schuur Hospital. The 
patient’s name was recorded once, together with a study number, on a list 
kept separately from the patient CRFs and thereafter all study data was 
labeled with the study number and not the name to maintain confidentiality of 
patient identity. Only the study team has access to this data. 
 
3.10 Collation of data 
Data was collected on an anonymised CRF and transferred electronically to 
an Excel (Microsoft® Excel® for Mac 2011) database. Patient identifiers were 
kept in a locked filing cabinet in a locked office.  
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3.11 Assessment of raw data 
3.11.1 Determination of neurocognitive function 
3.11.1.1 Global	  deficit	  score	  
For the primary outcome the GDS was used as a binary outcome measure 
with a GDS < 0.50 being normal and a GDS of ≥ 0.50 indicating cognitive 
impairment (55).  
 
The recognised way to obtain a GDS is as follows: 
1. Calculate a Z score.  
A Z score is derived as follows: 
z = (X - µ) / σ 
where: z is the Z-score, X is the patient’s raw score, µ is the sample 
population mean raw score, and σ is the standard deviation of the population. 
 
2. Calculate a T score.  
To transform a Z score to a T score: 
t = (10 x z) + 50 
where: t is the T-score, z is the Z-score. 
 
The T-score for each test in a cognitive domain is added up and divided by 
the number of tests for that domain (ranging from two to four tests in our 
study). An overall T score for each cognitive ability domain is hereby 
rendered. See illustrating Figure 3.2. This is a slight modification of the 
method described by Carey et al. (55), where each neuropsychological test is 
assigned a T-score, which is then converted to a deficit score, after which all 
the deficit scores are averaged to yield a GDS. Our method of calculating a 
domain summary T-score, which is then converted to a deficit score, has been 
used in other studies of HIV cognition in developed and developing countries 
(96, 97). Our cognitive battery spans eight cognitive domains and each 
domain does not include the same number of tests (e.g. speed of information 
processing was assessed by four tests whereas executive functioning was 
assessed by two tests). We therefore chose the domain-averaging method to 
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prevent bias brought about by over- or under-emphasis of domain-specific 
impairment. The potential misclassification of a patient as cognitively 
impaired, due to overrepresentation of a domain with a higher number of 
neuropsychological tests assigned to it, may hereby be lessened.  
 
For each cognitive test, the primary raw score is generally used to generate 
the T-score (e.g. when using the HVLT as a test of verbal memory, the 
delayed recall score is used rather than a percentage retained score or 





Figure 3.2: The normal distribution curve  
From https://commons.wikimedia.org/wiki/File:The_Normal_Distribution.svg. (Accessed 
12/08/2017) 
 
3. Calculate a deficit score.  
The T score for each cognitive ability domain is then assigned a deficit score, 




T-scores Deficit score Impairment descriptor 
≥ 40 0 Normal 
39-35 1 Mild 
34-30 2 Mild to moderate 
29-25 3 Moderate 
24-20 4 Moderate to severe 
≤19 5 Severe 
Figure 3.3: A Conversion Table for Transforming T Scores into Deficit Scores 
From Carey et al 2004: “Predictive validity of global deficit scores in detecting 
neuropsychological impairment in HIV infection”, J Clin Exp Neuropsychol. 2004 (55) 
 
Adding the Deficit Scores from each cognitive domain, and dividing this by the 
total number of domains, calculates the GDS. T scores of 40 or more (which 
indicate performance within normal limits) are assigned a deficit score of 0, 
whilst T scores in the impaired range are assigned progressively higher 
scores. This method of summarising the results emphasises poorer 
performance, whereas performances in the normal range will not be 
distinguished from those performances above average. This allows for the 
detection of more subtle impairment, which may otherwise be lost in simple 
mean calculations across test results.  
 
A cut point (for determination of global impairment) of ≥ 0.50 has been shown 
to have good diagnostic power: sensitivity: 0.77, specificity: 0.92, positive 
predictive power: 0.88, negative predictive power: 0.83. The overall diagnostic 
accuracy rate, when compared to clinical ratings by experienced 
neuropsychologists, was previously reported as 0.85 (55). In the study by 
Carey et al, it was further shown that 93% of the participants who had a GDS 
of ≥ 0.50, also had impairment in at least two ability domains as determined 
by clinical ratings (55). This is important, as the diagnostic criteria for HAND 
require diagnosis of impairment in at least two ability domains.  
The GDS approach has a further advantage in that it provides a continuous 
measure of impairment in addition to a categorical measure. 
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3.11.1.2 Classification	  of	  HAND	  
In 2007 the research criteria for diagnosis of HAND was updated (28). The so-
called Frascati criteria for HAND defines three subgroups:  
1. ANI, which is characterised by mild cognitive impairment (scoring between 
one and two standard deviations below the mean in at least two cognitive 
domains) in the absence of functional impairment. 
2. MND with a similar level of cognitive impairment as the ANI group but 
additional functional impairment. 
3. HAD with more severe cognitive impairment (more than two standard 
deviations below the mean in at least two cognitive domains) with significant 
functional decline. 
 
When assigning Frascati criteria, the Woods criteria are used for guidance 
(98). Here it states:  
“If Learning and Memory are the only two domain ratings greater than or 
equal to five, then carefully re-examine the percent retained (i.e., secondary) 
scores before assigning a global rating.  
i. If the memory impairment is primarily attributable to poor 
learning, then do not double penalize the participant when as- 
signing a global rating (i.e., do not factor in the Memory domain 
rating when assigning the global rating).  
ii. However, if there is evidence for deficits in both learning and 
retention, then the global rating should reflect the impairment in 
both of these domains” (98) 
With this in mind, the results of all patients with impaired Z scores in only the 
domains of learning and memory were further scrutinised by calculating a Z-
score for the percentage of visual or verbal material retained. If the Z-score for 
the percentage retained was less than one standard deviation below the 
mean the patient was not assigned as having cognitive impairment (effectively 
only one domain impaired). Conversely, if the Z-score for the percentage 
retained was greater than one standard deviation below the mean, this 
suggested that memory was impaired in addition to poor learning and the 
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patient was assigned with mild or severe impairment (depending on the Z-
scores for these domains). 
 
3.11.1.3 Determination	  of	  Neuropsychological	  impairment	  
When grading functional impairment as none, mild or severe impairment, we 
were guided by the following from the Frascati group (28): 
1) “Self report of increased assistance with at least two instrumental activities 
of daily living (IADLs).”  We measured this with the IADL- modified for South 
Africa (56, 57). A score of 14 out of 16 indicated mild impairment while a 
score of 13 or less indicated severe impairment. 
2) “Inability to perform some aspects of a previous job, not ascribed to 
physical difficulty.”  If a patient could still return to work but some adjustments 
were necessary or more difficulty was experienced, we assigned this as mild 
functional impairment. If a patient was unable to return to work at all, this was 
rated as severe impairment. 
3) “Increased difficulty with aspects of cognition in daily life.” These included 
difficulties with memory for recent events; understanding conversations or 
reading materials; word finding; planning activities; problem solving; 
concentrating; thinking clearly or logically; finding his or her way about; 
calculating; or following directions or instructions. The scale used to measure 
this was the PAOFI (58). This 33-item questionnaire uses a Likert scale and 
higher scores indicate greater impairment while a score of zero indicates 
normal functioning. A score of two or three was assigned mild impairment 
(provided that the difficulty was in two or more cognitive domains) while a 
score of four or more was assigned severe impairment (provided that the 
difficulty was in four or more cognitive domains). In the presence of significant 
depression (Beck Depression Inventory score ≥ 20) (91), symptom reporting 
may be biased and in such cases we sought informant report of similar 
difficulties. If there were no corroborated reports we did not assign the patient 
with functional impairment, as symptoms of cognitive impairment may be 
overestimated in patients with depression (87).  
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The scale administered for the purpose of informant report of cognitive decline 
was the DECO scale which compares current cognitive functioning with status 
one year before (59). It spans multiple areas of cognitive functioning. The 19 
questions can be answered as no change (score 2), not as well (score 1) or 
much worse (score 0). Therefore lower scores equate to greater impairment. 
Mild impairment was assigned to scores of 31 through 36. Severe impairment 
was assigned to scores of 30 or less (providing the response was much worse 
and occurred in four or more cognitive domains). 
 
Patient self-report was combined with informant reports to assign a final 
functional impairment grading. This meant that a patient who denied any 
functional impairment might still be classified as impaired based on informant 
reports of such decline. 
 
3.12 Statistical analysis 
The difference between the cognitive outcomes for two groups was analysed 
in three ways:  for our primary hypothesis, we employed a dichotomous 
outcome for the presence or absence of cognitive impairment using the 
validated cutoff of the GDS of 0.5. For this, a Fisher’s exact test was 
employed. Secondly, the GDS can be used as a continuous variable to grade 
severity of cognitive impairment. The GDS is not normally distributed, and 
therefore a Mann-Whitney U test was used. Lastly, the Frascati/AAN 
categories of HAND are a useful measure to estimate differences between 
groups especially as it incorporates level of functioning. The Fisher’s exact 
test was used for this analysis.  
 
For predictors of cognitive outcome, we used the Mann-Whitney U test for 
non-parametric variables (age, level of education, CD4 lymphocyte count, 
duration of ART use). Fisher’s exact test was used for categorical variables 




Spearman’s Rho statistic was used to test the association between QOL and 
the GDS. The asymptotic Kruskal-Wallis Test was used to test how well the 
Frascati criteria correlated with the GDS. 
 
Cohen’s D (Hedges G adjustment was made for small sample size) was 
applied to calculate an effect size for differences between groups in Z-scores 
across cognitive domains. The Mann-Whitney test was used to generate a p-
value for these Z-scores.  
 
I performed the descriptive statistics, calculation of norming study means and 
standard deviations (SDs), calculation of the GDS, and classification of 
Frascati criteria myself. Dr Reshma Kassanjee (UCT Dept of Statistical 
Sciences) assisted with univariate analysis of baseline measures and Dr 
Jonathan Ipser (UCT Dept of Psychiatry, National Research foundation fellow) 
assisted with analysis of cognitive data.  
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Chapter 4: Results 
 
This chapter will commence with a description of the study population 
followed by the results of the primary and secondary aims.  
 
4.1 Description of the study cohort 
We recruited patients from three district level hospitals in Cape Town. The 
flowchart of patients enrolled and patients who followed up six months after 











































Figure 4.1: Flowchart for screening, recruitment and final cognitive analysis of exposed (TBM) 
and non-exposed (extra-CNS TB) patients 
*Patients known to be alive as evidenced by active patient records on the National Health 
Laboratory Services (NHLS) web-based reporting system at or after the six-month follow-up 
date. 
Assessed for eligibility (n=193) 
• 131 extra-CNS TB 
patients 
•
Excluded  (n= 108) 
• 77 extra-CNS TB patients 
• 31 TBM patients 
See details Error! Reference source 
Figure 4.3:
TBM patients completed cognitive testing (n= 
15) 
  
Patients diagnosed with TBM (n=27) 
 
Extra-CNS TB patients completed cognitive 
testing (n= 26) 
 
Patients diagnosed with extra-CNS TB (n=52)  
 
Allocation	  
Six	  month	  follow-­‐up	  
Enrolled (n=85) 
• 54 extra-CNS TB patients 




Further Exclusions  (n=6) 
• 2 extra-CNS TB patients 
• 4 TBM patients 
 
Enrolled (n=79) 
• 52 extra-CNS TB patients 
• 27 TBM patients 
 
Death (n=10)  
Lost to follow-up (n=2) 
• Relocation=1 
• Uncontactable, 
known to be 
alive*=1 
Death (n=10) 
Lost to follow-up (n=16) 
• Declined further 
participation=4 
• Relocation=2 
• Uncontactable, known 





A total of 108/193 patients screened were not suitable for enrollment. The 
reasons for exclusion from the TBM group is shown in Figure 4.2, and 
exclusion from the extra-CNS TB group are shown in Figure 4.3. 
 
  
Figure 4.2: Reasons for exclusion from the TBM group amongst patients screened 
Only definite and probable TBM patients were included, possible TBM patients were excluded as 
they did not meet clinical research criteria for higher grades of diagnostic certainty.  
*Other reasons include: Multi-drug resistant TB, level of education less than Grade 7, substance 
abuse, previous CNS Toxoplasmosis, previous traumatic brain injury, declined HIV test, on TB 
treatment for more than 10 days.  
Abbreviations: CNS = Central nervous system; extra-CNS TB = Tuberculosis outside of the 



















Figure 4.3: Reasons for exclusion from the extra-CNS TB group amongst patients screened 
*Other reasons include: Prior HIV dementia, non-standard TB drug regime, level of education < 
Grade 7, headache, withheld consent.  
Abbreviations: CNS = Central nervous system; extra-CNS TB = Tuberculosis outside of the 
central nervous system; HIV = Human immunodeficiency virus; MDR TB = Multi-drug resistant 
tuberculosis.  
 
There were six further exclusions from the group of 85 patients who were 
initially enrolled. Two extra-CNS TB patients were excluded: one patient had 
non-tuberculous mycobacterium cultured while the other patient had multi-
drug resistant (MDR)-TB. Four TBM patients were excluded: three with MDR-
TB and one patient with only possible TBM rather than probable TBM (this 
transpired on review of symptom duration). 
 
The final group of patients enrolled consisted of 79 patients: 27 (34.2%) with 
TBM and 52 (65.8%) with extra-CNS TB.  
 
The baseline socio-demographic characteristics (Table 4.1) and clinical 























more females. The median age of all participants was 35 years (interquartile 
range [IQR] 29-40) and ranged from 19 to 65 years. The average time of 
schooling was 10 years. Forty-five (57.0%) of the patients were not on ART at 
the time of enrollment. This includes patients who were ART naive as well as 
patients who defaulted treatment. Patients presented with acute symptoms 
(relating to the system involved, i.e. coughing in an extra-CNS TB patient or 
headache in a TBM patient) of on average a week duration on a background 




Table 4.1: Socio-demographic details for the enrolled cohort 
 TBM group (n=27) Extra-CNS TB group (n=52) 
Median (IQR) 
or N (%) 
Range Median (IQR) 
or N (%) 
Range 
Age (years) 35 (28-40) 20-65 34 (30-38) 19-58 
Sex (female) 17 (63) - 27 (52) - 
Level of education 
(years) 
101 (10-11) 7-16 10 (9-11) 7-14 
Employed (yes) 10/242 (42) - 21 (40) - 
Smoking (yes) 6/243 (25) - 14 (27) - 
Alcohol use (yes) 4/234 (17) - 18 (35) - 
AUDIT score 6 (3-9) 1-10 7 (3-10) 1-185 
On ART (yes) 9 (33) - 25 (48) - 
Duration of ART 
(weeks) 
23 (14-63) 2-287 6 (4-27) 2-1036 
1Level of education unknown for eight of the TBM patients. 
2Employment status unknown for three of the TBM patients.  
3Smoking status unknown for three of the TBM patients.  
4Alcohol use unknown for four of the TBM patients.  
5One patient reported alcohol use initially with an AUDIT score of 16 but subsequently on review 
six months later admitted higher intake with an AUDIT score of 18. He was not excluded but the 
AUDIT scores between groups were analysed.  
Abbreviations: ART = Anti-retroviral therapy; AUDIT = Alcohol use disorders identification test; 
Extra-CNS TB = Tuberculosis outside of the central nervous system; IQR = Interquartile range; 




Table 4.2: Clinical symptomatology for the enrolled cohort 
 TBM group (n=27) Extra-CNS TB group (n=52) 
Median (IQR) or 
N (%) 
Range Median (IQR) or 
N (%) 
Range 
Duration acute symptoms 
(in days) 
7 (7-13) 1-23 7 (5-14) 1-96 
Duration systemic 
symptoms (in days) 
30 (19-49) 10-63 30 (21-61) 14-151 
Systemic symptoms 









Night sweats 12 (44) - 26 (50) - 
Respiratory 14 (52) - 45 (87) - 
Gastro-intestinal 3 (11) - 29 (56) - 
Acute (neurological) 














Vomiting 12 (44) - - - 
Confusion 17 (63) - - - 
Neck pain 21 (78) - - - 
Seizures 4 (15) - - - 
Photophobia 9 (33) - - - 
Abbreviations: Extra-CNS TB = Tuberculosis outside of the central nervous system; IQR = 
Interquartile range; TBM = Tuberculous meningitis. 
 
Amongst the 52 extra-CNS TB patients, the presenting complaint was 
respiratory in nature in most patients (87%). There were no focal neurological 
signs or meningism in this patient group. Three patients had mild 
disorientation to the date:  this was ascribed to hyponatremia and urinary tract 
infection in one; hypoxia and fever of 40° Celsius in another; and hypoxia in 
the last patient (who also had a normal lumbar puncture). The site of TB was 
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confirmed to be pulmonary in 51 patients, with additional sites including 
abdominal (n=16), adenitis (n=2), haematological (n=2), cardiac (n=6), genito-
urinary (n=3), and miliary (n=4). 
 
The clinical signs are summarised in Table 4.3. Most patients presented with 
tachycardia, but high-grade fever was unusual. Twenty-four TBM patients 
(89%) had meningism and seven patients (26%) had focal neurological signs. 
These focal signs included cranial neuropathies in two patients, hemiparesis 
in five patients and cerebellar signs in two patients. According to the BMRC 
TBM disease severity grading (60), the majority of patients were classified as 
grade two. No patients met grade three classification.  
 
Table 4.3: Clinical signs in the enrolled patients 
 TBM group (n=27) Extra-CNS TB group (n=52) 
Median (IQR) or 
N (%) 
Range Median (IQR) or 
N (%) 
Range 
Pulse 115 (98-126)  72-153 121 (107-132) 79-164 
Temperature 36.6 (36.4-37.5)  36-40 36.5 (36.2- 37.1) 35.4-39.3 
Meningism in TBM 
patients (yes) 
24 (89) - - - 
GCS 14 (13-15) 11-15 15 (15-15) 141-15 
Focal signs (yes) 7 (26) - 0 (0) - 











Grade 2 20 (74) - - - 
1 Three extra-CNS TB patients had mild disorientation to the date.  See text for details. 
2No patient had a BMRC grading of three.  
Abbreviations:  BMRC = British medical research council; Extra-CNS TB = Tuberculosis outside 




Laboratory results are shown in Table 4.4. All patients had full blood count 
and renal function tests. All but one patient had a chest x-ray (CXR). Anemia 
and hyponatremia was common, but a peripheral blood leucocytosis, renal 
failure and significant liver enzyme abnormalities were rare.  
 
Table 4.4: Laboratory and radiological investigations for the enrolled patients  
 
 
TBM group (n=27) Extra-CNS TB group (n=52) 
Median (IQR) or 
N (%) 
Range Median (IQR) or 
N (%) 
Range 
CD4 lymphocyte count, cells/µL 80 (44-152) 2-281 60 (20-119) 1-402 
Hb, g/dL 11 (9.7-12.2) 6.4-14.6 8.9 (7.5-10.4) 2.8-14.3 
White cell count, x109/L 5.9 (4.3-6.7) 2.9-9.7 8.3 (5.7-10.8) 2.3-23.4 
Urea, mmol/L 3.5 (3.0-5.1) 1.8-13.6 5.4 (3.3-7.9) 1-71.3 
Creatinine, µmol/L 58 (51-67) 35-219 76 (54-116) 33-795 
Sodium, mmol/L 128 (121-133) 114-139 130 (125-132) 117-137 
Alanine transferase, U/L1 36 (21-61) 10-479 29 (20-57) 9-272 











Neutrophils, x106/L 13 (0-36) 0-133 0 (0-0) 0-0 
Glucose, mmol/L 1.7 (1.2-2.6) 0.5-8.8 3.5 (3.2-4.0) 2.4-5.3 
Protein, g/L 2.68 (1.64-4.93) 0.28-35.00 0.24 (0.22-0.26) <0.1-0.36 
Radiological investigation  (Nr 















Abdominal ultrasound  6/10 (60) - 15/24 (63) - 
Echocardiogram  1/2 (50) - 6/12 (50) - 
CT Brain  5/8 (63) - - - 
1Performed in 47/52 extra-CNS TB patients and in 23/27 TBM patients.  
2Performed in 27/52 extra-CNS TB patients and in 14/27 TBM patients.  
3A lumbar puncture was performed in seven patients with extra-CNS TB.  
4A lumbar puncture was performed in all TBM patients.  
Abbreviations: CSF = Cerebrospinal fluid; CT = Computed Tomography; CXR = Chest X-ray; 
Extra-CNS TB = Tuberculosis outside of the central nervous system; Hb = Haemoglobin; IQR = 
Interquartile range; Nr = Number; TBM = Tuberculous meningitis. 
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The TB diagnoses for each group are shown in Table 4.5. For the TBM group, 
definite TBM was diagnosed in 12 patients with the remaining 15 patients 
having probable TBM, as defined by clinical research criteria (4). The CSF 
findings were as expected:  a lymphocytic-predominant meningitis with raised 
protein and low glucose levels. Eight patients had a CT brain scan performed:  
five (63%) of these patients had findings supportive of TBM as outlined in the 
clinical research criteria (4); one patient had changes suggestive of either 
progressive multifocal leucoencephalopathy or HIV encephalitis; the other two 
patients had a normal scan. It is noteworthy that five out of the eight patients 
who had a CT brain scan performed died prior to the six-month follow-up 
point. TB was proven outside of the CNS compartment in 23 (85%) patients:  
all these patients had respiratory involvement (either sputa or suggestive 
CXR) with additional sites including abdominal (n=8), miliary (n=7), adenitis 
(n=1), cardiac (n=1), and genito-urinary tract (n=1). Of note, all of the patients 
classified as definite TB also had evidence of TB elsewhere. There were 
therefore four probable TBM patients who did not have TB proven elsewhere. 
The first patient had a suggestive CSF picture and a contrasted CT Brain 
scan suggestive of TBM with a tuberculoma, basal meningeal enhancement 
and cerebral oedema. The other three patients had no other systems involved 
but scored 10 on the TBM research criteria (six points for symptoms, four 
points for CSF findings). Two of the patients without extra-CNS involvement 
did not have any sputum samples sent for testing while the other two had 
sputum tested for GeneXpert analysis but not for microscopy or culture. All 
but one patient were prescribed steroid treatment together with their TB 









Table 4.5: TB diagnoses for enrolled patients 
 TBM group (n=27) Extra-CNS TB group (n=52) 
Median (IQR) 
or N (%) Range 
Median (IQR) 













Probable 15 (56) - - - 
TB outside of CNS for TBM patients (yes) 23 (85) - - - 










Disseminated - - 20 (38) - 













Abdominal - - 16 (31) - 
Adenitis - - 2 (4) - 
Haematological - - 2 (4) - 
Cardiac - - 6 (12) - 
Genito-urinary - - 3 (6) - 
Miliary - - 4 (8) - 
Steroids prescribed at discharge (yes) 26 (96) - 3 (6) - 
Abbreviations: CNS = Central nervous system; CSF = Cerebrospinal fluid; CT = Computed 
Tomography; CXR = Chest X-ray; Extra-CNS TB = Tuberculosis outside of the central nervous 
system; Hb = Haemoglobin; IQR = Interquartile range; TBM = Tuberculous meningitis. 
 
Regarding the extra-CNS TB group, the number of patients with disseminated 
TB was 20 (38%) vs 32 (62%) patients with single-site TB. Forty-two patients 
had definite TB with the remaining ten patients having probable extra-CNS 
TB. Three patients were prescribed steroid treatment upon discharge: two for 
suspected Pneumocystis jiroveci pneumonia and one for TB pericarditis. 
Seven patients had a lumbar puncture (LP) performed and the CSF results 
were all normal. Reasons for LP included: positive serum Cryptococcal Latex 
Antigen Test (CLAT) in which case the CSF CLAT was negative; sepsis 
screen; and as part of a further search for TB. 
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Investigations of alternative diagnoses for TBM and potential confounders of 
cognitive performance are summarised in Table 4.6. A minority of patients 
had Vitamin B12 or thyroid function tests. Roughly half the patients had some 
form of syphilis testing. One TBM patient had a weak positive CSF 
Fluorescent Treponemal Antibody (FTA), but CSF Venereal disease research 
laboratory (VDRL) testing was negative as was serum FTA and VDRL. This 
patient tested positive on a CSF TB GeneXpert test. A few patients tested 
positive for serum FTA:  seven extra-CNS TB patients and one TBM patient. 
In six of these patients, the serum VDRL and/or Rapid plasma reagin (RPR) 
was negative. The remaining two patients (both with extra-CNS TB) had low 
VDRL titres of one and two respectively. All but two TBM patients had CSF 
CLAT testing performed. All patients had CSF sent for bacterial culture and 
these were all negative. 
 
Table 4.6: Further special investigations performed which may have an impact on cognitive 
outcomes 
 TBM patients  
(N=27) 




% Nr/ nr 
performed 
% 
Vitamin B12 (low) 0/5 0 0/16 0 
s-RPR or VDRL (positive) 0/13 0 2/291 7 
s-FTA (positive) 1/12 8 7/25 28 
TSH (abnormal) 0/7 0 0/5 0 
CSF FTA (positive) 1/152 7 0/4 0 
CSF RPR and/or VDRL (positive) 0/5 0 0/3 0 
CSF CLAT (positive) 0/25 0 0/6 0 
1Weak titres of 1 and 2 respectively.  
2Weak positive.  
Abbreviations: CLAT = Cryptococcal latex antigen test; CNS = Central nervous system; CSF = 
Cerebrospinal fluid; Extra-CNS TB = Tuberculosis outside of the central nervous system; FTA = 
Fluorescent Treponemal antibody; Nr = number; RPR = Rapid plasma reagin; s = serum; TBM = 
Tuberculous meningitis; TSH = Thyroid stimulating hormone; VDRL = Venereal disease research 
laboratory.  
 
Following enrollment, eighteen patients were lost to follow-up (see Figure 
4.1). Ten TBM and 10 extra-CNS TB patients died, that is, almost double the 
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number of TBM compared to extra-CNS TB (37% vs. 20.8%) patients. Despite 
the clinical significance of this finding, the trend to higher mortality in the TBM 
group did not reach statistical significance (p-value = 0.175).  
 
Regarding time to death, the exact date of death was known for the majority 
of patients, but in the two patients where this was not known, the date of 
death was taken as the date of the two-month follow-up phone call. Fourteen 
out of the 20 patients died within the first two months after enrollment with an 
equal distribution of seven patients in each group. In the TBM group, half of 
the patient deaths (5 patients) occurred within the first week, contrasting with 
no deaths in the first week in the extra-CNS TB group. The remaining six 
patients (three in each group) died after two months but prior to the six-month 
follow-up period.  
 
The median time to death in the TBM group was 33 days (IQR 4-82). In the 
extra-CNS TB group the median time to death was 42 days (IQR 26-78). This 
trend of earlier deaths in the TBM group is further demonstrated in the 




Figure 4.4: Graph of cumulative survival in both groups   
Abbreviations: Extra-CNS TB = Tuberculosis outside of the central nervous system; TBM = 
Tuberculous meningitis. 
 
Because a relatively large number of patients died (and disproportionately so 
between the two groups), this is potentially an important confounder of 
predictors of poor cognitive outcomes in the patients who survived. In other 
words, it is possible that the patients who died would have performed worse 
cognitively, had they survived. We therefore looked for significant differences 
in baseline measures for patients who died and those who survived in each 
group. The comparison of the TBM group and extra-CNS TB group are shown 






Table 4.7: Comparison of baseline measures in TBM patients who survived and those who died 
 Survivors 








Age (years) 35 (25-38) 20-46 38 (34-43) 29-65 0.083 
Sex (female) 11, 65% - 6, 60% - 1.000 
Level of education (years) 10 (10-11)1 7-16 8 (8-9)2 7-10 0.038* 




25-281  46 (35-75) 2-163 0.014* 
ART duration (weeks) 33 (15-59) 13-152 23 (13-155) 2-287 1.000 
On ART (yes) 6, 35% - 3, 30% - 1.000 
Alcohol use (yes) 3, 18% - 1/63, 17% - 1.000 
Smoking (yes) 4, 24% - 2/74, 29% - 1.000 
The one patient whose mortality status was unknown is not included in this analysis.  
1LoE unknown for one patient.  
2LoE unknown for seven patients.  
3Alcohol use unknown for four patients.  
4Smoking status unknown for three patients.  
*P-Value < 0.05  
Abbreviations: ART = Anti-retroviral therapy. IQR = Interquartile range. 
 
There were two significant differences between the TBM patients who 
survived and those who died: level of education and CD4 lymphocyte count. 
The lower level of education in patients who died should be interpreted with 
caution, as this information was only known for three of the patients who died. 
Patients who died had a lower mean CD4 lymphocyte count. Furthermore, 





Table 4.8: Comparison of baseline measures in extra-CNS TB patients who survived and those 
who died 
 Survivors 
(N = 38) 
 
Deaths 
(N = 10) 
 
P-Value 
 Median (IQR) 
or N (%) 
Range Median (IQR) 
or N (%) 
Range  
Age (years) 35 (28-38) 19-50 35 (32-43) 24-58 0.286 
Sex (female) 21 (55) - 5 (50) - 1.000 
Education (years) 10 (9-11) 7-14 10 (9-11) 7-12 0.381 
CD4 lymphocyte 
count (cells/µL) 
68 (23-128) 1-402 76 (23-128)  9-348 0.639 
ART duration at 
enrollment (weeks) 
7 (4-21) 2-10361 4 (4-5) 2-171 0.374 
On ART (yes) 19 (50) - 5 (50) - 1.00 
Alcohol use (yes) 14 (37) - 2 (20) - 0.460 
Smoking (yes) 12 (32) - 2 (20) - 0.701 
The four patients whose mortality status was unknown were not included in this analysis. 
1Patient with vertical transmission of HIV, on ART from neonatal period.  
Abbreviations: ART = anti-retroviral therapy; IQR = Interquartile range. 
 
There were no significant differences between extra-CNS TB patients who 
survived and those who died.  
 
A total of 41 patients (26 [63%] patients with extra-CNS TB and 15 [37%] 
patients with TBM) were therefore seen at six months after enrollment for 
comprehensive cognitive testing. The demographic and clinical variables were 




Table 4.9: Comparison of demographic and clinical measures in the two groups of patients who 
followed up at six months after TB diagnosis 
 TBM 
(N = 15) 
Extra-CNS TB 
(N = 26) 
P-Value 
Median 
(IQR) or  
N (%) 
Range Median 
(IQR) or  
N (%) 
Range  
Age (years) 28 (25-40) 20-46 35 (30-41) 19-50 0.212 
Sex (female) 10 (67) - 11 (42) - 0.197 
Education (years) 10 (10-11) 7-16 10 (9-11) 7-14 0.944 
CD4 lymphocyte count 
(cells/µL) 
103 (61-194) 25-281 74 (28-112) 1-402 0.078 
On ART (yes) 5 (33) - 16 (62) - 0.111 
ART duration in weeks1 48 (15-107) 13-152 7 (3-24) 2-10362 0.069 
Alcohol use (yes) 3 (20) - 10 (38) - 0.305 
AUDIT score ≥ 8 1 (7) - 6 (23) - 0.232 
Smokers (yes) 4 (27) - 10 (38) - 0.512 
1ART duration in weeks at enrollment.  
2Duration = 20.4 years in a patient with vertical transmission of HIV.  
Abbreviations: ART = Anti-retroviral therapy; AUDIT = Alcohol Use Disorders Test; Extra-CNS TB 
= Tuberculosis outside of the central nervous system; IQR = Interquartile range; TBM = 
Tuberculous menigitis. 
 
There were no significant differences between the two groups on any of the 
measures reported. Patients were slightly older in the extra-CNS TB group 
and included a slightly lower proportion of females. There was a trend to 
significance for the difference in CD4 lymphocyte count with a lower CD4 
lymphocyte count in the extra-CNS TB group. This finding may partly be 
explained by the fact that TBM patients with low CD4 lymphocyte counts were 
significantly more likely to die as shown in Table 4.7. The TBM group had a 
lower proportion of patients on ART at enrollment, but for the TBM patients 
who were on ART, the duration was longer than for the extra-CNS TB 
patients. We looked at the difference between groups relating to alcohol use 
(yes or no) but also at differences on the scores of the AUDIT questionnaire. 
A cut-off score of ≥ 8 on this measure indicates potentially hazardous or 
harmful drinking (medium level drinking). We excluded all patients with high 
level drinking or dependence (score ≥ 16). There were more patients who 
consumed alcohol in the extra-CNS TB group and also more patients with an 
 50 
AUDIT score of ≥ 8 in this group. The difference was not statistically 
significant. There was a similar discrepancy between groups relating to 
smoking:  a higher proportion of patients in the extra-CNS TB group smoked, 
but this did not reach statistical significance.  
 
At six-months follow-up, we also looked at measures of depression and 
apathy that might impact on cognition and confound performance (see Table 
4.10). 
 
Table 4.10: Depression and apathy questionnaire scores 











AES-I 28 (24-35) 20-57 25 (24-28.8) 19-69 0.288 
Abbreviations: AES-I = Apathy evaluation scale, informant version; BDI = Beck Depression 
Inventory scale, version II; Extra-CNS TB = Tuberculosis outside of the central nervous system; 
IQR = Interquartile range; TBM = Tuberculous menigitis. 
 
There was no significant difference on apathy scores between the two groups 
when analysed as a continuous variable. We also analysed the AES-I score 
as a binary measure (normal or impaired), using a cut-off score of ≥ 34 to 
delineate apathy as based on norms from a healthy population (94). There 
were five patients (33%) who were apathetic in the TBM group compared to 
three (12%) in the extra-CNS TB group (p-value 0.12). Two of the three (67%) 
apathetic patients in the extra-CNS group were impaired on the GDS. In 
contrast, only two of the five (40%) apathetic patients in the TBM group were 
impaired on the GDS. Two TBM patients who were apathetic were also 
depressed as scored by the BDI. One extra-CNS TB patient who was 
apathetic was also depressed.  
 
There was no significant difference on depression scores (as a continuous 
variable) between the two groups. Looking at the scores on the BDI-II as a 
categorical measure, standard cut-off scores (91) to delineate mild (14-19), 
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moderate (20-28) or severe (29-63) depression were applied. For patients 
who were moderately or severely depressed, three (20%) TBM patients and 
two (8%) extra-CNS TB patients fell into this category. This difference was not 
statistically significant. One patient from each group was also impaired on the 
GDS.  
 
Functional impairment was subjectively measured using the modified IADL 
scale and PAOFI, or using collateral information from the DECO 
questionnaire. Results are shown in Table 4.11. 
 
Table 4.11: Questionnaires assessing functional impairment 






IADL 16 (15.5-16) 2-16 16 (16-16) 13-16 0.501 
DECO 38 (31.5-38) 0-38 38 (38-38) 16-38 0.273 
PAOFI 0 (0-1.5) 0-30 0 (0-0) 0-10 0.258 
Abbreviations: DECO = Deterioration in cognitive observee; Extra-CNS TB = Tuberculosis 
outside of the central nervous system; IADL = Instrumental activities of daily living, modified for 
South Africa; IQR = Interquartile range; PAOFI = Patient assessment of functional impairment; 
TBM = Tuberculous menigitis. 
 
The scores on the modified IADL were comparable between the groups. 
There was a non-significant trend towards TBM patients having more 
impairment on DECO and PAOFI questionnaires.  
 
The mRS scores were different between the groups with a median score of 0 
(IQR 0-1; range 0-2) for the extra-CNS TB group and 1 (IQR 0-2; range 0-4) 
for the TBM group. This difference rendered a near-significant p-value of 0.06.  
 
4.2 Primary Aim 
Our primary aim was to determine the cognitive outcome of TBM patients 
compared to extra-CNS TB patients at six months after TB treatment initiation. 
We hypothesised that TBM patients will have a more severe degree of 
cognitive impairment as measured by the continuous GDS than patients with 
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extra-CNS TB and that the proportion of patients with cognitive impairment 
will be larger for the TBM patients than extra-CNS TB patients as measured 
by the binary GDS with a cutoff of ≥ 0.5. 
 
4.2.1 Continuous GDS analysis 
The mean GDS for the entire cohort was 0.34 (SD 0.69) with a range of 0 - 
2.625. The median for the group was 0 (IQR 0- 0.188). The histogram of the 
GDS for the study cohort is shown in Figure 4.5 and demonstrates the skew 
distribution with the majority of patients having a score of 0.  
 
 
Figure 4.5: Histogram of the GDS for all patients 
GDS = Global deficit score  
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Continuous GDS analysis for each group was performed. The histogram for 
the GDS of the TBM patients is shown in Figure 4.6 and for the extra-CNS TB 
patients in Figure 4.7. 
 
The extra-CNS TB patients had a median score of 0 with an IQR of 0 - 0.125. 
Scores ranged from 0 - 2.375. The TBM patients had a median score of 0 as 
well, but with an IQR of 0 – 0.5, thereby designating all patients in the fourth 
quartile to the impaired range of ≥ 0.5. Scores ranged from 0 - 2.625. 
 
 
Figure 4.6: Histogram of the GDS for the TBM patients 




Figure 4.7:  Histogram of the GDS for the extra-CNS TB patients.  
Abbreviations: extra-CNS TB = Tuberculosis outside of the central nervous system. GDS = 
Global deficit score. 
 
The boxplot of the GDS distribution amongst the two cohorts is shown in 
Figure 4.8. This again demonstrates the wider spread of interquartile range 




Figure 4.8: Boxplot of the GDS for TBM and extra-CNS TB patients 
The boundaries of the box are Tukey’s hinges. A line inside the box identifies the median. The 
length of the box is the interquartile range (IQR) computed from Tukey’s hinges. Values more 
than three IQR’s from the end of a box are labeled as extreme, denoted with an asterisk (*).  
Abbreviations: Extra-CNS TB = Tuberculosis outside of the central nervous system; GDS = 
Global deficit score; IQR = Interquarile range; TBM = Tuberculous meningitis. 
 
The difference between the groups’ continuous GDS was not significant with a 
p-value of 0.439. 
 
4.2.2 Binary GDS analysis 
Other than the degree of impairment as measured by the GDS, we also 
wanted to quantify the absolute number of patients who were impaired. For 
this purpose we used the recognised GDS cutoff of ≥ 0.50. Across groups, 
nine (22%) patients were cognitively impaired. Five patients were from the 
TBM group and four patients were from the extra-CNS TB group. Therefore, 
33% of the TBM patients were impaired compared to 15% of the extra-CNS 
TB patients. Despite double the proportion of affected patients in the TBM 
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group, this clinically significant difference did not reach statistical significance 
(p=0.248).  
 
To assess the effect of biased patient deaths (with a higher proportion of 
deaths in the TBM group) on cognitive outcomes, we also looked at whether 
TBM exposure status correlated with GDS classification and death. There was 
no significant association between TBM exposure and GDS classification or 
death (p = 0.285). 
 
4.3 Secondary Aims 
4.3.1 Cognitive outcomes by Frascati criteria  
Our first secondary aim was to classify patients into HAND categories:  
normal; ANI; MND; or HAD. Definitions for these classifications have been 
discussed in Chapter 2. Across groups, eight (20%) patients were impaired, 
with four patients in each group, which equates to 27% of TBM patients and 
15% of extra-CNS TB patients. Three patients were classified as ANI (7%), 
two (5%) as MND and three (7%) as HAD. The distribution of these 
classifications by TBM exposure is shown in Table 4.12. To assess whether 
patients who were exposed to TBM performed worse than extra-CNS TB 
patients by Frascati criteria, we drew up a contingency table (see Table 4.12). 
 
Table 4.12: Contingency table of TBM exposure status and Frascati classification  
 Normal ANI MND HAD p-Value 
























Abbreviations: ANI = asymptomatic neurocognitive impairment; Extra-CNS TB = Tuberculosis 
outside of the central nervous system; HAD = HIV-associated dementia; MND = mild 
neurocognitive disorder; TBM = Tuberculous meningitis 
 
There was no significant difference in cognitive performance by Frascati 
criteria for the two TB groups.  
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To assess cognitive impairment and associated impact on functional status, 
we further divided patients into two groups based on the Frascati criteria as 
follows: patients with normal cognitive performance and asymptomatic 
neurocognitive impairment in the first group; and patients with mild 
neurocognitive disorder and HIV associated dementia in the second group. 
This dichotomised classification has real-life meaning, as the first group, by 
definition, has normal daily functioning, whereas the second group is 
functionally impaired (albeit to mild degrees for MND and severely for HAD).  
 
Only five patients (12.2%) had functional impairment (classification of 
functional impairment has been outlined in Chapter 3):  two (8%) patients in 
the extra-CNS TB group and three (20%) in the TBM group. This difference 
was not statistically significant (p-value = 0.336). Three of these five patients 
had severe functional impairment while the remaining two patients had mild 
functional impairment. These five patients all had a GDS of ≥ 1. This leaves 
three patients with impaired cognition but normal functioning. These three 
patients had mildly impaired cognition by Frascati criteria and were thus 
classified as ANI.  
 
There was one patient with a GDS of 0.5 who was not rated as impaired by 
Frascati criteria. This patient (number 90) is discussed in further detail below 
in section 4.3.2.1. There were no patients who were impaired by Frascati 
criteria and had a normal GDS.  
 
There were eight patients who were functionally impaired but performed 
normally on cognitive tests. Four of these patients had mild functional 
impairment and four had severe functional impairment. Looking at the four 
patients with severe functional impairment: one patient had significant 
depression and apathy as measured by the BDI-II and AES-I questionnaires 
respectively. The second patient was not depressed but was markedly 
apathetic (highest score of the entire cohort). The third and fourth patients 
were mildly depressed but not significantly apathetic.  
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To assess how well the Frascati criteria correlated with the GDS, we ran the 
asymptotic Kruskal-Wallis Test. There was a highly significant increase of 
GDS across HAND groups, indicating a very good correlation between these 
two measures of cognitive impairment (p-value <0.001). 
 
4.3.2 Description of cognitive impairment by domains  
We assessed whether there were differences in performance across domains 
between the two groups. We grouped the 21 cognitive tests into eight 
cognitive domains as discussed in Chapter 3. Performance by domain is 
shown in Table 4.13. The Z-scores were derived from local norms as 
discussed in Chapter 3. 
 








(N = 26) 
Mean Z-score 
(SD) 




(95% CI)1 P-Value 



































1Hedges G correction was used due to small sample sizes. 
Abbreviations:  Extra-CNS TB = Tuberculosis outside of the central nervous system; SD = 
Standard deviation; TBM = Tuberculous meningitis.  
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Looking at the cohort as a whole, the most impaired domains were that of 
information processing speed; attention and working memory; and executive 
function. The same applies to each group individually with the three lowest 
mean Z-scores being in those specific domains. The effect sizes for the 
differences between groups were small to medium (Cohen’s D between 0.2 
and 0.5) for all domains except memory. For memory performance, the effect 
size of the difference between groups was negligible. If we examine the p-
values, the strongest trend towards significant differences between groups 
was in the visuospatial domain (p=0.176). In this domain, the TBM patients 
performed worse with a mean Z-score of -0.38 (SD=1.06) contrasting with a 
near-normal performance in the extra-CNS TB group with a mean Z-score of -
0.06 (SD 0.98). 
 
A description of the performance on subtests within each cognitive domain is 























































-0.50 (-1.18, 0.18) 
-0.69 (-1.42, 0.03) 
 
0.06 (-0.61, 0.73) 









HVLT-R trials 1-3 








0.22 (-0.45, 0.9) 














0.04 (-0.63, 0.71) 




Information processing speed 
TMT A 
CTT I 













-0.40 (-1.07, 0.28) 
-0.36 (-1.04, 0.32) 
0.00 (-0.67, 0.67) 






Attention/ Working memory 
Digit span forward 
Digit span backward 
Mental control 












0.05 (-0.62, 0.73) 
0.52 (-0.16, 1.21) 
0.10 (-0.58, 0.77) 
















0,32 (-0.36, 1.00) 







Category fluency  















0.32 (-0.35, 1.00) 
 
0.06 (-0.61, 0.73) 
 























0.20 (-0.47, 0.88) 
0.33 (-0.34, 1.01) 
0.41 (-1.05, 0.23) 






1The mean Z-score for each test is reported using patient raw scores compared to local 
normative data.  
Abbreviations: BVMT-R = Brief visuospatial memory test – revised; CTT I = Color trails test I; 
CTT II = Color trails test II; Extra-CNS TB = Tuberculosis outside of the central nervous system. 
HVLT-R = Hopkins verbal learning test – revised; JLOT = Judgement of line orientation test; 
SCWT = Stroop Color Word Test; SD = Standard deviation; TBM = Tuberculous menigitis; TMT A 
= Trail making test A.  
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There were no large effect sizes noted for the subtests of each cognitive 
domain. There were moderate effect sizes for the following tests:  the 
dominant and non-dominant hand Grooved Pegboard test with the TBM 
patients performing slower; the backward digit span with the TBM patients 
having a shorter span; and the mental alternation test with TBM completing 
fewer correct number-letter sequences in the allocated time.  
 
4.3.2.1 Description	  of	  patients	  with	  impaired	  cognition	  
The performance of the nine patients who were impaired by the GDS will now 
be further discussed. It warrants stating that because a fixed research 
protocol is followed, an accurate description of these patients’ neurocognitive 
deficit is not always possible. A qualitative impression by taking a more 
extensive history is lost in the research setting and further probing of areas of 
impairment is not supported in this context. Also, this battery does not assess 
language to a sufficient extent. With these caveats in mind, a vignette for each 
of the nine cognitively impaired patients is created. Z-scores within one SD of 
the mean is taken as a normal performance; between one and two SD below 
the mean as mild impairment; more than two SD below the mean as moderate 
to severe. 
 
1. Patient number 23, TBM patient, GDS = 2.5 
She is a 29-year-old lady who was ART naive when she was diagnosed with 
definite TBM based on symptoms and CSF TB GeneXpert positivity. She was 
started on TB treatment and high dose oral Prednisone in hospital and on 
ART six weeks after diagnosis. She re-presented to hospital two months after 
diagnosis with worsening headache and a CSF protein of 13.8g/L (compared 
to a level of 1.6g/L at diagnosis) and an increasing CSF lymphocyte count. 
Her CT Brain was unremarkable. She was diagnosed with TBM-IRIS and 
treated with high dose Prednisone. Three months later, she presented again, 
with confusion and leg weakness and was assessed as having TBM-IRIS with 
myelo-meningo-radiculopathy and given another course of oral Prednisone. 
She was transferred to a rehabilitation facility. She was cognitively assessed 
at this facility at six months after TBM diagnosis.  
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She denied any impairment in her IADLs but complained of mild memory 
difficulty. Her husband reported a definite decline in cognition since time of 
TBM diagnosis. She was not apathetic or depressed.  
 
Her motor speed was slow for finger tapping and the grooved pegboard test 
with a summary Z-score of -1.6.  
 
Her verbal learning on the HVLT was impaired:  she recalled four, six and 
seven words for the three learning trials respectively (Z-score -1.8). Her 
verbal memory was very poor as she could only recall four out of the 12 
words after a delay, giving her a Z-score of -2.2. Her verbal percentage 
retained score generates a slightly better Z-score of -1.7. She did much 
better, however, on the recognition task where she correctly identified 11/12 
words with no false positive responses.  
 
In terms of visual learning on the BVMT, she scored two, four and three out 
of 12 for the three respective trials (Z-score -0.7). Her visual memory was 
very poor, however, as she could not correctly reproduce any of the six 
figures after a delay. With prompting she had four true positive responses and 
two false positive responses. This translates to a very poor Z-score of -3.8 for 
visual recognition memory.  
 
On tests of information processing speed she performed poorly: more than 
two standard deviations below the norm for TMT A, CTT 1 and digit symbol 
coding. She performed slightly better on the Symbol Search test (see Figure 





Figure 4.9: Symbol Search test for patient number 23 
Symbol search requires correctly identifying the presence of target symbols on the right from 
either of the two symbols on the left, under time pressure. Slow processing speed is 
demonstrated with eleven responses in two minutes. 
 
Regarding attention, her forward digit span was within normal limits with her 
correctly repeating a number string of five once. Working memory was within 
normal limits on the backward digit span test where she could muster a string 
of three numbers. She had somewhat impaired performances on the mental 
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alternation test and mental control. Overall, her summary Z-score for the 
domain of attention and working memory was -1.3. 
 
Testing of her executive functioning revealed impaired performance. On the 
SCWT, she gave just 17 responses in 45 seconds, giving her a Z-score of -
1.7. On CTT 2, she took just over 4 minutes to complete the task (compared 
to a mean time of 116 seconds for the sample population). Her summary Z-
score for this domain was -2.3. 
 
Performance on the two category and single action fluency tasks was clearly 
impaired with all her scores more than two SDs below the mean. She 
generated six words for the fruit and vegetable category compared with the 
population mean of 14. She could only generate one verb in one minute 
(population mean 10.4). Her summary Z-score for fluency was -2.3. 
 
In terms of visuospatial functioning, she performed very poorly on the JLOT 
with only one correct response (correctly identifying the orientation of the two 
paired lines, Z-score -3.1). Her performance on the CLOX was also impaired 
with a score of 8/15 (Z-score -1.7) for the spontaneous drawing (see Figure 
4.10) and 11/15 (Z-score -3.4) for the copy (see Figure 4.11). Her unprompted 
drawing showed a concrete approach with the watchstraps drawn, poor 
planning and incorrect placement of the hands. Her copy again showed poor 
planning and crowding of numbers on the right half of the clock face. This total 
score of 19 is well below the norm (25) and generates a Z-score of -2.3. Her 




Figure 4.10: Clock drawing on CLOX 1 task for patient number 23 
Patient was asked to draw a clock that says 1:45. Image not to scale.  
 
 
Figure 4.11: Clock copy on CLOX 2 task for patient number 23  
Patient was asked to copy examiner’s clock as shown on the left. Image not to scale. 
 
In summary, this patient attended well and was motivated. She was impaired 
in all eight domains tested. She had impaired verbal learning and poor 
retention of both the verbal and visual material that she had learnt. For the 
verbal material, she clearly benefitted from prompting, but this was less 
striking for visual material. In addition, she had slow motor and mental 
processing speed; poor executive functioning; poor generativity and poor 
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visuospatial skills. Although one could argue that the spontaneous drawing on 
the CLOX 1 task is loaded on both an executive and visuospatial basis, her 
performance on the copying task was also very impaired, suggesting 
additional visuospatial impairment. This is in keeping with her performance on 
the JLOT, which was the worst of all 41 patients tested. The above picture 
would suggest a frontal-subcortical process with additional visuospatial 
impairment. 
 
2. Patient number 33, TBM patient, GDS = 1 
This 36-year-old lady was ART naive when she presented with meningitic 
symptoms and signs. She was diagnosed with definite TBM based on a 
positive CSF TB culture.  
 
She had no intercurrent hospital admissions and was tested six months after 
diagnosis. She reported normal daily functioning although her sister reported 
mild cognitive deterioration. She was not depressed or apathetic.  
 
Her motor speed was normal.  
 
Verbal learning was mildly impaired (Z-score -1.1) while visual learning was 
normal (Z-score - 0.8). An example of her learning of the third trial of the 
BVMT is shown in Figure 4.12. Note the impaired accuracy of the figures as 
well as poor placement and poor spacial use of the page.  
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Figure 4.12: Third learning trial on the BVMT for patient number 33 
Note examiner scoring marks on the sheet: L=location, A= accuracy. The patient scored 4 for 
this attempt. The target figures shown to patient for 10 seconds prior to her drawing are shown 
in the lower right corner. Image not to scale. 
BVMT = Brief visuospatial memory test.  
 
Her verbal and visual memory was normal and she retained all of the words 
she learnt on the HVLT and retained 75% of the visual material.  
Speed of information processing was impaired:  TMT A took 76 seconds to 
complete (Z-score -2.2), while she scored between one and two standard 
deviations below the mean for the other three tests. This gave her a summary 
Z-score of -1.7.  
In terms of attention, her forward digit span was borderline impaired at four 
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digits (Z-score -1.0). Her working memory was much more impaired, 
however, with a backward digit span of two words on one trial only (Z-score -
2.1). Performance on mental control and mental alternation tests were also 
impaired, with a summary score for attention and working memory of -1.4.  
On tests of executive functioning, her performance on the SCWT was 
normal. She was very slow to complete CTT 2 at 221 seconds compared to 
the population mean of 116 (Z-score -2.2). Her summary Z-score for this 
domain was -1.6.  
For fluency she was mildly impaired on both semantic categories, but 
performed in the normal range for action fluency. Interestingly, her verb 
generation in one minute (10 words) was better than her animal generation (7 
words), whereas the population shows an opposite trend (more words 
generated for semantic categories than for verbs). Her summary Z-score for 
fluency was -1.1.  
Regarding visuospatial functioning, her JLOT was impaired with only 10/30 
pairs identified correctly (Z-score -1.3). Her unprompted clock drawing on the 
CLOX 1 task (see Figure 4.13) showed a disorganised approach and 
switching of numbers 6 and 12. There was also incorrect placement of the 





Figure 4.13: Clock drawing on CLOX 1 task for patient number 33  
Patient was asked to draw a clock that says 1:45. Image not to scale. 
 
On her copying of the clock, (see Figure 4.14) however, the circular outline 
was distorted, as was the number spacing. An impression of a rushed 
approach was noted and planning was again poor (Z-score for CLOX 2 task -
3.4). Her visuospatial summary Z-score is -1.8. 
  
Figure 4.14: Clock copy on CLOX 2 task for patient number 3  
Image not to scale 
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Overall, her impairments were mild and in the domains of information 
processing speed, working memory, executive functioning, and visuospatial 
functioning. A frontal-subcortical process is likely and may be impacting on 
her performance on the visuospatial tests, but seperate pathology impacting 
visuospatial processing cannot be ruled out. 
 
3. Patient number 52, extra-CNS TB patient, GDS=1 
This 37-year-old man, on ART for seven years, was diagnosed with 
pulmonary TB based on symptoms and a suggestive CXR. He had no further 
hospital admissions and was assessed at six months. The patient had a slight 
stammer and this may have hampered his performance on verbal timed tasks 
(e,g, mental alternation test). 
 
Neither the patient nor his father reported any functional impairment. He was 
not apathetic or depressed. 
 
His motor speed was normal. 
 
In terms of verbal learning, he recalled six, four and seven words on the 
three trials of the HVLT respectively (Z-score -1.8). For verbal memory he 
recalled six words, which is slightly impaired (Z-score -1.3). However, his 
retention memory of 85% was normal and he correctly recognised 10/12 
words. 
 
For visual learning, his figure reproduction was poor with scores of zero, one 
and three for the three trials of the BVMT respectively (Z-score -1.5). His third 




 Figure 4.15: Learning trial 3 of the BVMT for patient number 52  
Annotation by examiner: L= Location; A= Accuracy. Image not to scale. 
BVMT = Brief visuospatial memory test.  
 
For visual memory after a delay, he scored three, which paralleled his best 
learning performance, thereby retaining 100% of information learnt. This 
image is shown in Figure 4.16. He correctly recognised five out of the six true 







Figure 4.16: Delayed recall of visual stimulus from the BVMT for patient number 52  
Annotation by examiner: L= Location; A= Accuracy. Image not to scale. 
BVMT = Brief visuospatial memory test.  
 
On speed of information processing, he was slightly slow on the CTT 1, 
digit symbol coding and symbol search tasks with a normal TMT A 
performance. A summary Z-score for this domain was -1.4.  
 
His test of attention was poor, with a forward digit span of three only (Z-score 
-2.2). His working memory was normal with a backward digit span of three. 
His performance on the mental control task was impaired with a Z-score of -
2.2, but he performed normally on the mental alternation task. His summary 
Z-score for this domain was -1.4.  
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For tasks tapping into executive functioning, he was mildly impaired on the 
SCWT and the CTT 2. This rendered a summary Z-score of -1.6.  
 
For the fluency tasks, he was mildy impaired for both semantic categories but 
performed normally on the action fluency task by generating seven verbs. A 
summary Z-score of -1.2 was rendered.  
 
For visuospatial testing, he performed well on the JLOT, correctly identifying 
22 pairs (population mean 16). His CLOX drawing and copy was slightly 
rushed and not detailed, but placement of the hands and numbers were 
reasonable. He scored 24/30. This normal performance was reflected in a 
summary Z-score of 0.3.  
 
 
Figure 4.17: Clock drawing on CLOX 1 task for patient number 52 
Patient was asked to draw a clock that says 1:45. Image not to scale. 
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Figure 4.18: Clock copy on the CLOX 2 task for patient number 52 
Image not to scale. 
 
In summary, this patient’s performance was characterised poor attention and 
working memory, which likely impacted on his ability to learn. His memory of 
the material that he learnt, however, was good. He further had mildly impaired 
information processing speed, executive functioning and semantic fluency. 
This picture would be compatible with a mild frontal-subcortical process. 
 
4. Patient number 74, TBM patient, GDS = 2.625 
This 44-year-old man, ART naive, presented with a six week history of 
confusion and not reporting to work. He had night sweats and back pain 
during this time with difficulty walking. He then developed headache and 
cough with hemoptysis, which prompted admission to hospital. He was 
diagnosed with probable TBM based on symptoms and a suggestive CSF. He 
did not have evidence of TB elsewhere. Testing for neurosyphilis and 
cryptococcal meningitis was negative. Vitamin B12 levels and thyroid function 
tests were normal. He was discharged on TB treatment and oral steroids and 
ART was initiated a month later. He improved initially, but four months after 
diagnosis he re-presented to hospital with psychotic behaviour. Repeat CSF 
testing showed improvement in CSF parameters and a contrasted CT Brain 
revealed bilateral periventricular and subcortical white matter disease, early 
hydrocephalus and mild brain atrophy. Differential diagnoses considered 
included Efavirenz or Isoniazid induced psychosis; psychosis secondary to 
TBM; or HIV associated neurocognitive disorder. His ART and TB drug 
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regime was adjusted to allow cessation of Efavirenz and Isoniazid. He was 
assessed at a psychiatric inpatient facility seven months after TBM diagnosis. 
Of note, the patient was on psychotropic drugs (Lithium and Haloperidol) at 
time of testing. He had pressure of speech and was disinhibited. 
 
Both self-reported and informant-reported questionnaires of functioning 
revealed marked perceived impairment. He scored in the moderate range for 
depression and was deemed markedly apathetic on the AES-I. 
 
Motor speed was slow, with his grooved pegboard times being the slowest of 
the entire cohort (dominant hand Z-score -4.5). He performed better on finger 
tapping tests. His summary Z-score was -1.8. 
 
Verbal learning was very poor with six, four and four words recalled for the 
three respective trials of the HVLT (Z-score -2.6). After a delay, he could not 
recall one word from the list, giving him a Z-score of -4.2 for verbal memory. 
On the test of recognition memory he identified 9/12 true positives, which is 
also impaired (Z-score -2.7, population mean is 11.5/12), but did indicate a 
benefit from prompting.  
 
In contrast to verbal learning, his visual learning was normal (three, two and 
four points for the three learning trials of the BVMT respectively). See Figure 
4.19 for his third trial drawing. However, after a delay, he could not recall any 
figures correctly, yielding a Z-score of -2.1. His delayed drawing attempt was 
interesting for some perseverative features and is shown in Figure 4.20. For 
the recognition memory task, he gave 5/6 true positive responses (Z-score -
1.7), which again was not normal but much better than spontaneous recall of 




Figure 4.19: Drawing of trial three of the BVMT for patient number 74  
Annotation by examiner: L= Location; A= Accuracy. Image not to scale. 




Figure 4.20: Delayed recall drawing of the BVMT for patient number 74  
Note perseveration of the diamond shape. Annotation by examiner: L= Location; A= Accuracy. 
Image not to scale. 
BVMT = Brief visuospatial memory test. 
 
On tests of speed of information processing this patient was drastically 
impaired. He took 121 seconds to complete the TMT A (contrast with 
population mean of 41 seconds, yielding a Z-score of -5.1). His CTT 1 took 
double the time of the population mean while his digit symbol coding and 
symbol search were also impaired. His symbol search is shown in Figure 




Figure 4.21: Symbol Search test for patient number 74 
Symbol search requires correctly identifying the presence of target symbols on the right from 
either of the two symbols on the left, under time pressure. Patient had only seven correct 
responses in two minutes.  
 
His attention was assessed by his forwards digit span and this was five (Z-
score 0.2). His working memory as assessed by backwards digit span was 
two (Z-score -1.5). Mental alternation and mental control tests were also 
impaired between one and two SDs below the mean. His summary score for 
this domain was -1.4. 
 
Tests of executive functioning highlighted marked difficulty. On the SCWT 
he correctly read out only 13 words in the allocated 45 seconds. For the CT 2, 
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he took nearly six minutes to complete this compared with the population 
mean of under two minutes. The summary Z-score for this domain was -3.5. 
 
On tests of fluency, he could name eight animals, 12 fruit and vegetables, 
and six verbs. This yielded a summary Z-score of -1.2.  
 
On visuospatial tests, he performed within the normal range for both JLOT 
and CLOX tests with a summary Z-score of -0.9. His CLOX 1 drawing is 
shown in Figure 4.22, which demonstrates the disorganised and perseverative 
numbering and asymmetric spacing of the numbers. On the copying task in 
Figure 4.23, some minor errors with minute and hour hands persist, but shows 
improvement on his CLOX 1 drawing. 
 
 
Figure 4.22: Clock drawing on CLOX 1 task for patient number 74 




Figure 4.23: Clock copy on CLOX 2 for patient number 74 
Image not to scale. 
 
In summary, this patient’s performance has to be assessed in the context of a 
psychotic state and the presence of neuroleptic drugs. The first standout 
feature of his performance is marked slowing (mental processing speed to a 
greater extent than motor speed); which may in part by accounted for by 
extrapyramidal side-effects of anti-psychotic drugs. His attention was normal, 
although some fluctuation of attention cannot be ruled out. He had poor verbal 
learning and poor verbal and visual memory which both demonstrated some 
benefit from prompting. Furthermore, he demonstrates a marked dysexecutive 
syndrome. Generativity/fluency and visuospatial skills were relatively spared. 
These features would be compatible with severe white matter/subcortical and 
frontal pathology. 
 
5. Patient number 19, extra-CNS TB, GDS = 2.375 
This 51-year-old lady, ART naive, presented with diarrhoea, vomiting and 
fever. She was diagnosed with pulmonary TB based on sputum GeneXpert 
positivity and a suggestive CXR. She was started on TB treatment and ART 
was initiated a month after diagnosis. She was assessed at six months after 
diagnosis.  
 
She reported some difficulty managing her finances, but was otherwise 
independent in her activities of daily living (ADLs). She had mild visual 
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complaints on the PAOFI. Her daugther denied significant changes in her 
cognition and she was not deemed apathetic or depressed.  
 
Her motor speed was slightly slowed for her dominant hand, but normal for 
her non-dominant hand, rendering a normal summary score. 
 
Her verbal learning was impaired, with four, five and seven words learnt on 
the three learning trials of the HVLT (Z-score -2.1). She recalled three words 
after a delay, thereby retaining less than half of what she learnt. Her verbal 
memory Z-score was -2.7. On the recognition task, she gave 10/12 true 
positive responses with one false positive response. This generates a Z-score 
of -1.6 for recognition memory. 
 
Her visual learning was somewhat better with two, two and three points 
respectively for the three learning trials of the BVMT (Z-score -1.0). Her third 
learning trial is shown in Figure 4.24. This demonstrates a poor learning 
curve, but because the population mean learning score for the three trials is 
12.9 (SD 5.9), she was only bordeline impaired. 
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Figure 4.24: Drawing of the third learning trial of the BVMT for patient number 19  
Annotation by examiner: L= Location; A= Accuracy. Image not to scale. 
BVMT = Brief visuospatial memory test. 
 
Her delayed recall of the BVMT is shown in Figure 4.25, demonstrating good 
retention of the little that she learnt. The score of three renders a Z-score of -
0.9. On the test of visual recognition memory, she correctly identified 5/6 
figures but also gave two false positive answers. This was impaired compared 




Figure 4.25: Delayed recall drawing of the BVMT for patient number 19 
Annotation by examiner: L= Location; A= Accuracy. Image not to scale. 
BVMT = Brief visuospatial memory test. 
 
Speed of information processing was markedly impaired. For both TMT A 
and CTT 1 she had a very slow performance with a Z-score of between three 
and four SDs below the mean. For digit symbol coding and symbol search 
tests, she scored between two and three SD below the mean. Her summary 
Z-score for this domain was -2.7. 
 
Her attention was normal as assessed by a forward digit span of five (Z-
score -0.4). Her working memory was tested by her backward digit span 
which was only two (Z-score -1.5), as well as tests of mental alternation and 




Testing of executive function yielded a slightly impaired performance on the 
SCWT but a markedly slow completion of the CTT 2 at 276 seconds (Z-score 
-3.3). Her summary Z-score was -2.5. 
 
On the fluency tasks, she generated the names of six animals, eight fruit and 
vegetables and seven verbs. This was somewhat impaired with a Z-score of -
1.6 overall. 
 
Visuospatial functioning was impaired to a great extent. She could only 
correctly identify four line pairs on the JLOT (Z-score -2.5). On the CLOX 1 
task she scored extremely poorly (Z-score -3.6), her drawing is shown in 
Figure 4.26. There was no clear concept of the numbering or hands of the 
clock. There were six annotations/marks on the right side of the clock 
correlating with placement for six numbers but on the left side of the clock the 
markings do not correspond with standard numbering. The copy of the clock 
as shown in Figure 4.27 is much better but the number spacing is not 
symmetrical, minute and hour hand placement incorrect, and planning was 
again poor (12, 6, 3 and 9 not placed first), yielding a Z-score of -3.4. Her 
summary score for the visuospatial domain is -3.1. 
 
 
Figure 4.26: Clock drawing on the CLOX 1 task for patient number 19 
Patient was asked to draw a clock that says 1:45. Image not to scale. 
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Figure 4.27: Clock copy on the CLOX 2 task for patient number 19  
Image not to scale. 
 
Overall, the areas of moderate to severe impairment were speed of 
information processing, executive functioning and visuospatial functioning. 
She had poor working memory, which might have impacted on verbal 
learning, which was poor. Her verbal memory was also poor, but did benefit 
from prompting. Her memory performance and some aspects of the clock 
drawing supported a dysexecutive syndrome. However, the very poor 
performance on the JLOT task argues for some visuospatial difficulty in 
addition to the marked frontal-subcortical syndrome.  
 
6. Patient number 22, extra-CNS TB, GDS = 0.75 
This 35-year-old man was started on ART two weeks prior to presenting with 
a cough. He was diagnosed with disseminated TB-IRIS based on a 
suggestive CXR and abdominal ultrasound, and a positive sputum GeneXpert 
test. His CD4 lymphocyte count was 7 cells/µL. He was discharged on TB 
treatment and improved. He did not have any intercurrent admissions and 
was able to return to work as a labourer.  
 
The patient and his brother denied any difficulty with ADLs or cognition. He 
was not depressed or apathetic.  
 
His motor speed was within normal limits. 
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His verbal learning was impaired with three, six and seven words learnt on 
the three trials of the HVLT (Z-score -2.1). His delayed recall was five, 
thereby retaining 71% of what he learnt. His recognition memory was poor, 
with only 8/12 true positives identified and one false positive response. This is 
very impaired compared to the population mean of 11.5 true positives and 
rendered a Z-score of -3.8, but was nonetheless an improvement on his 
spontaneous recall.  
 
His visual learning was also impaired with two, one and two points 
respectively for the figure reproduction on the three learning trials of the 
BVMT (Z-score -1.3). The third trial drawing is shown in Figure 4.28. For his 
delayed recall of the figures (see Figure 4.29), he scored 2 out of a possible 
12, thereby retaining the little that he had learnt. His Z-score for visual 
memory was -1.3. During the recognition task, he positively identified 4 
figures correctly, with one false positive. This poor recognition contrasted with 
the population mean of 5.8 true positives, but was also an improvement on his 




Figure 4.28: Drawing of the third trial of the BVMT for patient number 22  
Annotation by examiner: L= Location; A= Accuracy. Image not to scale.  





Figure 4.29: Delayed recall drawing on the BVMT for patient number 22 
Annotation by examiner: L= Location; A= Accuracy. Image not to scale 
BVMT = Brief visuospatial memory test. 
 
Tests of speed of information processing were largely intact with a 
summary Z-score of -0.7. 
 
During testing of attention, his digit span forward was intact for a number 
string of four (Z-score -1.0). His working memory revealed a normal 
backward digit span of three on one trial. Mental alternation and mental 
control tests were borderline impaired. The summary Z-score was -1.1. 
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Regarding executive functioning, he performed in the mildly impaired range 
on the SCWT but performed better than the mean on the CTT 2, thereby 
yielding a normal summary score for this domain. 
 
For fluency, he generated 10 animal names, eight fruit and vegetables and 
six verbs. This gave a summary Z-score of -1.3. 
 
His performance on visuospatial tasks approximated the population mean 
scores and his summary Z-score was -0.1. His clock drawing and clock copy 
are shown in Figure 4.30 and Figure 4.31 respectively. Although his clock 
drawing wasn’t accurate in terms of hand placement and symmetry, his copy 
was near normal, except that he didn’t place the 12, 6, 3 and 9 first.  
 
 
Figure 4.30: Clock drawing on CLOX 1 task for patient number 22 
Patient was asked to draw a clock that says 1:45. Image not to scale. 
 
 
Figure 4.31: Clock copy on CLOX 2 task for patient number 22 
Image not to scale. 
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Overall, this patient performed in the impaired range of the GDS largely due to 
poor learning and memory. His verbal and visual learning was poor, but he 
retained 71% of the verbal and 100% of the visual matter that he learnt. 
Based on how the GDS is calculated though (absolute score on recall, not the 
percentage retained), he was “penalised” on memory scores as well as 
learning. In his case visual and verbal recognition memory was also sub-par, 
but he recognised more material than he recalled spontaneously. This would 
support a mixed picture of impaired encoding and retrieval. Furthermore, he 
had borderline impaired performances on attention/working memory and 
fluency domains, which lends further weight to common frontostriatal 
pathology contributing to the final impaired GDS score.  
 
7. Patient number 90, TBM patient, GDS = 0.5 
This 36-year-old man; not on ART at time of hospitalisation as he had 
defaulted treatment two years prior; presented with headache, neck pain, 
confusion and a flaccid paraparesis. He was diagnosed with probable TBM 
based on symptoms, a suggestive CSF profile, an abnormal CXR and a 
supportive CT Brain scan (basal meningeal contrast enhancement). He was 
started on TB treatment and high dose steroids and was transferred to a 
rehabilitation facility because of leg weakness. He re-presented three months 
later with headache and worsening leg weakness. His repeat CSF showed an 
increase in protein and lymphocyte counts. He was diagnosed with TBM-IRIS 
and steroid therapy was reinstated. He improved and was discharged from 
the rehabilitation hospital five months after diagnosis. He was assessed at 6.5 
months after diagnosis. His limb strength had improved to normal. 
 
There was no self-reported or informant-reported impairment in daily 
functioning or decline in cognitive skills. He was not apathetic or depressed. 
 
His motor speed was normal.  
 
His verbal learning was very poor with three, four and five words respectively 
recalled on the three learning trials of the HVLT (Z-score -3.0). His delayed 
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recall was three (Z-score -2.3), thereby retaining 60% of what he learnt, 
which was also impaired. His recognition memory was impaired with 9/12 
true positive responses, but did show an improvement compared to 
spontaneous recall. The Z-score generated hereby was -2.7.  
 
For visual learning he scored one, three and five respectively for the three 
learning trials on the BVMT, giving him a total learning score of nine, which 
was within normal limits. On the delayed recall task he scored four, thereby 
retaining 80% of what he learnt. Both the absolute recall score and 
percentage-retained score were within normal range. On the visual 
recognition task, he gave 5/6 true positive responses.  
 
Overall, verbal learning and memory were therefore clearly impaired with 
near-normal scores for visual learning and memory.  
 
His information processing speed was normal for all four tasks undertaken. 
 
Regarding attention, his forward digit span was five, but he had impaired 
working memory with a backward digit span of two only. On tasks of mental 
alternation and mental control his performance was borderline. However, his 
summary Z-score for the domain was still within normal at -0.9. 
 
For tests of executive functioning, he was mildly impaired on the SCWT (Z-
score -1.3) but this was countered by a better-than-normal performance on 
the CTT 2 task. His summary score was normal.  
 
On tests of fluency, he gave a normal performance by generating 14 animals, 
11 fruit and vegetables, and nine verbs.  
 
On tests of visuospatial functioning he performed very well with the joint 
highest score on the JLOT of 24 (Z-score 1.5) and CLOX score of 28 (Z-score 





Figure 4.32: CLOX 1 drawing task for patient number 90 
Patient was asked to draw a clock that says 1:45. Image not to scale. 
 
 
Figure 4.33: CLOX 2 copying task for patient number 90 
Image not to scale. 
 
Overall, this patient performed very poorly on tasks of verbal learning and 
memory. He performed in the normal range for all other domains. It is 
interesting to note that his visual learning and memory was normal, 
suggesting some laterality with impairment in the dominant hemisphere. His 
verbal memory deficit did show benefit from prompting (recall of three words, 
recognition of 9/12 words) but his percentage-retained score was still below 
normal. This pattern could be described as a mixture of encoding and retrieval 
difficulty. A more pervasive dysexecutive syndrome was not seen. 
 
This patient was not rated as impaired by the Frascati HAND criteria as two or 
more domains have to be involved and if those two domains are learning and 
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memory the secondary scores of percentages retained are used instead. In 
this case our patient had a Z-score for verbal and visual memory (using 
percentage retained) of -0.9. Hereby, he was impaired only in the single 
domain of learning.  
 
8. Patient number 6, extra-CNS TB patient, GDS = 1.5 
This 30-year-old lady presented on ART, which was reinstated after her 
defaulting treatment the previous year. She was diagnosed with disseminated 
TB based on symptoms, a positive sputum GeneXpert result, radiological 
abdominal TB features, and a pericardial effusion on echocardiogram. She 
was treated with TB treatment and oral prednisone for the pericardial effusion.  
 
Both the patient and her mother reported a decline in daily functioning and 
cognitive skills. She was also deemed apathetic on the AES-I with a high 
score of 59 (second highest of the entire cohort) and was moderately 
depressed. 
 
During the assessment, she struck me as apathetic and unmotivated.  
 
Her motor speed was slightly impaired with a Z-score of -1.2.  
 
Verbal learning was very poor with one, three and eight words recalled on 
the three respective learning trials of the HVLT (Z-score -3.0). Her delayed 
recall was three words, rendering low scores for absolute number of words 
recalled (Z-score -2.7) as well as the percentage retained (Z-score -2.9). Her 
recognition memory was much better with 11/12 true positive responses and 
one false positive response.  
 
Visual learning was also impaired with no correct figures reproduced in the 
first two learning trials of the BVMT and three points for the third trial (Z-score 
-1.7). This is shown in Figure 4.34. A slightly careless, unmotivated and 
disorganised approach is demonstrated. On the delayed recall task, she did 
not attempt any drawing (Z-score -2.1). On the recognition task, she had 4/6 




Figure 4.34: Learning trials 1, 2 and 3 (from left to right) on the BVMT for patient number 6 
Images not to scale. 
BVMT = Brief visuospatial memory test.  
 
On tests of speed of information processing, she was impaired on the digit 
symbol coding test where she only completed 17 items and these included 
five errors. However, she performed within normal limits for the CTT 1, TMT A 
and digit symbol search to generate a normal summary Z-score for this 
domain of -0.9. 
 
Attention was impaired:  she could repeat a string of four numbers forwards 
once. For working memory, her backward digit span was three. Tests of 
mental control and mental alternation were marginally impaired. Her summary 
Z-score was thus -1.3. 
 
Executive functioning was normal on the SCWT and slightly impaired on the 
CTT 2, yielding a normal summary Z-score. 
 
On tests of fluency she was marginally impaired for animal and fruit and 
vegetable fluency where she generated 10 and 11 words respectively. 
However, she had very diminished action fluency and could only name three 
verbs (population mean is 10). This led to a summary Z-score of -1.3. 
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She performed poorly on tasks of visuospatial functioning:  she could only 
correctly identify 3/30 line pairs on the JLOT (Z-score -2.7). For her CLOX 
tasks she averaged with Z-score of -1.6. Her spontaneous drawing of the 
clock showed poor planning, poor symmetry and poor self-monitoring. The 
patient then self-initiated a second clock with better number spacing but 
incorrect hand placement (Figure 4.35). Her copy was rushed and included 
some sectoring/tic marks (Figure 4.36). Her summary Z-score for this domain 
was -2.1.  
 
 
Figure 4.35: CLOX 1 drawing task for patient number 6 
Patient was asked to draw a clock that says 1:45. The patient self-initiated the second drawing 
below her first attempt. Image not to scale. 
 
 
Figure 4.36: CLOX 2 copying task for patient number 6 
Image not to scale. 
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In summary, this patient had a neurobehavioural syndrome characterised by 
marked apathy and globally impaired neuropsychological performance. She 
performed poorly in the domains of learning, memory and visuospatial 
functioning. Her learning and memory performance was characterised by 
impaired immediate and delayed free recall in the setting of relatively better 
recognition performance for both verbal and visual domains. Visuospatial 
functioning (as judged by her performance on the JLOT and some aspects of 
the CLOX tasks) was clearly impaired. Furthermore, she had milder 
impairment in the domains of motor speed, attention/working memory and 
fluency. The picture is compatible with a frontal-subcortical process with 
additional visuospatial impairment. The marked apathy may be explained by 
involvement of medial frontal-anterior cingulate circuitry (99). 
 
9. Patient number 68, TBM, GDS = 0.5 
This 40-year-old man presented with headache, vomiting and hiccups. He 
was not on ART after defaulting three years prior. He was diagnosed with 
probable TBM based on symptoms and a very suggestive CSF:  protein 
11.83g/L, lymphocyte count 1113 x106/L and glucose 0.7mmol/l. He was 
started on TB treatment and oral steroids, which was weaned after six weeks. 
He then re-presented a week after steroid treatment was stopped with ataxia 
and seizures. A CT Brain scan demonstrated basal and cortical 
leptomeningeal enhancement and vasogenic oedema. TBM-IRIS was 
diagnosed and steroid treatment was reinstated. Two weeks after this second 
course of steroids was weaned he again relapsed with worsening ataxia and 
limb weakness. A second CT Brain scan showed multiple tuberculomas. 
Toxoplasmosis and cryptococcal disease were excluded and TBM-IRIS was 
again diagnosed. He was restarted on oral steroids after which he improved. 
He was assessed in a rehabilitation facility at six months after enrollment. He 
was able to walk with a crutch and had a mild left hemiparesis and ataxia. 
 
Neither the patient nor his mother reported functional impairment or a decline 
in cognition. He was not depressed or apathetic. 
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On tests of motor speed, he was marginally impaired with a summary Z-
score of -1.0.  
 
For verbal learning, he recalled three, six and six words respectively on the 
three HVLT learning trials. This was impaired with a Z-score of -2.3. His 
delayed recall was good with nine words recalled (Z-score 0.2). He identified 
10/12 true positive stimuli on the recognition memory task. 
 
For visual learning, he showed a good learning curve with one, five and nine 
points scored on the three respective learning trials of the BVMT (Z-score 
0.3). This is shown in Figure 4.37. On the delayed recall task, he scored 
seven, which was better than the norm of 5.3. For the recognition task, he 
identified 5/6 objects as true positives.  
 
Figure 4.37: First learning trial (shown on the left) and third learning trial (shown on the right) of 
the BVMT for patient number 68 
Images not to scale. 
BVMT = Brief visuospatial memory test.  
 
On the tests of information processing speed, he was marginally impaired 
for CTT 1, TMT A and Digit Symbol Search. For digit symbol coding he scored 
more than two SD below the mean by only completing 16 correct digit-symbol 
pairs in the allocated time. His summary Z-score for this domain was -1.4. 
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For attention as tested by the digits forward test, he could repeat a string of 
four digits on one occasion (Z-score -1.6). For working memory, he could 
repeat only two digits backwards (Z-score -1.5). He was slightly impaired on 
the mental control task but normal on the mental alternation task. His average 
Z-score for this domain was -1.1. 
 
Testing executive functioning revealed some difficulty with the SCWT where 
only 16 words were read in the allocated time (Z-score -1.9). His performance 
on the CTT 2 was normal. A summary Z-score of -1.3 was obtained. 
 
His fluency was normal with 12 animals, 13 fruit and vegetables and 11 verbs 
generated. 
 
On testing visuospatial functioning, he performed better than the mean on 
the JLOT. For the CLOX task he fell within normal limits. His summary Z-
score for this domain was -0.2. 
 
In summary, this patient’s neuropsychological profile is of mild impairment in 
motor and information processing speed, executive functioning, and attention 
and working memory. This is compatible with a mild frontal-subcortical 
process.  
 
4.3.2.2 Summary	  of	  cognitive	  performance	  in	  patients	  with	  an	  abnormal	  GDS	  
The domain of attention and working memory was most commonly affected 
(in all but one patient), albeit to a mild extent only. Learning, memory, and 
fluency were impaired in all but two patients. The details of impaired cognitive 







Table 4.15: Breakdown of impairment by cognitive domain for the nine patients with a GDS ≥ 0.5   






Total Total Total 
Mild Mod Severe Mild Mod Severe 
Motor speed 4 3 1 
3 0 0 1 0 0 
Learning 7 3 4 
3 0 0 3 1 0 
Memory 7 3 4 
1 1 1 3 1 0 
Speed of information 
processing 
6 4 2 
2 1 1 1 1 0 
Attention & working 
memory 
8 4 4 
4 0 0 4 0 0 
Executive functioning 6 4 2 
2 1 1 1 1 0 
Fluency 7 3 4 
2 1 0 4 0 0 
Visuospatial skills 4 2 2 
1 1 0 0 1 1 
Mild impairment if Z-score between one and two standard deviations below the mean; moderate 
impairment if Z-score between two and three standard deviations below the mean; severe 
impairment if more than three standard deviations below the mean.  
Abbreviations: Extra-CNS TB = Tuberculosis outside of the central nervous system; GDS = 
Global deficit score; Mod = Moderate; TBM = Tuberculous menigitis.  
 
The most common neuropsychological pattern of impairment was a frontal-
subcortical picture. This was seen in eight of the nine patients. However, in 
four of these patients (50%), there was additional visuospatial impairment. 
The one patient who did not have a frontal-subcortical picture had an isolated 
deficit of verbal learning and memory only. Fluency was often impaired, 
usually only to a mild extent. We saw the pattern of worse action fluency 
compared to category fluency, as described in HAND literature (100), in one 
patient only. Interestingly, the converse was true for three patients with better 
action fluency than category fluency.  
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4.3.3 Predictors of poor cognitive outcome 
4.3.3.1 Predictors	  of	  poor	  outcome	  in	  both	  groups	  
In both cases and controls we postulated that higher age, female gender, 
smoking, alcohol use, lower level of education, lower CD4 lymphocyte count, 
shorter duration of ART at six months, and not being on ART at enrolment, 
would be predictors of worse outcome. Although we hypothesised that the 
presence of traditional vascular risk factors would predict worse cognitive 
outcome, only one patient was hypertensive and none of the patients were 
known to be diabetic or hypercholesterolaemic. This may be a reflection of a 
younger population with low prevalence of these risk factors or may be due to 
infrequent screening for these chronic illnesses at a primary care level. 
Therefore, due to the low prevalence of this risk factor in our cohort, this was 
not analysed.  
 
We analysed age, level of education, CD4 lymphocyte count, and duration of 
ART in two ways. Firstly as categorical variables with a binary split around the 
median (see Table 4.16) and subsequently as continuous variables (see 
Table 4.17). Gender, smoking, alcohol use, and ART use at enrolment, were 




Table 4.16: Predictors of cognitive outcome in both groups for categorical variables 
 GDS Impaired p-Value 
















































































Abbreviations: ART = Anti-retroviral therapy; GDS = Global deficit score.  
 
There is a trend for older age and shorter duration on ART (< 200 days) at six 
months follow-up to cause more impairment on the GDS, but this did not 
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reach statistical significance. The scatterplot of ART duration against GDS is 
shown in Figure 4.38. 
 
 
Figure 4.38: Scatterplot of the log of ART duration in days (at six months follow-up) against the 
GDS 
Abbreviations: ART = Anti-retroviral therapy; GDS = Global deficit score. 
 
Roughly double the proportion of patients who were not on ART at the time of 
enrolment were impaired on the GDS compared to those patients who were 
already on treatment. This difference did not, however, reach statistical 
significance. 
Table 4.17: Predictors of cognitive outcomes in both groups for continuous variables 
Continuous variable Association with binary GDS 
P-value 
Age (years) 0.18 
Level of education (years) 0.248 
CD4 lymphocyte count (cells/µL) 0.498 
Duration of ART (at six months follow-up) 0.345 
Abbreviations: ART = Anti-retroviral therapy 
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The continuous variables were analysed for an association with cognitive 
outcome, as shown in Table 4.17. There was again a trend for older age to be 
associated with worse cognitive outcome. The CD4 lymphocyte count was not 
significantly associated with cognitive outcomes. However, if one looks at the 
proportion of patients with a normal GDS vs impaired GDS vs patients who 
died, the results (Table 4.18) show a trend towards significance (p-value 0.18) 
with a lower CD4 lymphocyte count accounting for a higher proportion of 
patients who died.  
 
Table 4.18: Association of CD4 lymphocyte count (<60 vs ≥60 cells/µL) with GDS status or death 
 
GDS classification and death p-Value 
Normal Impaired Died 
CD4 lymphocyte  
count (cells/µL) 




% 42.3% 11.5% 46.2% 
≥60 Count 21 6 8 
% 60.0% 17.1% 22.9% 
Abbreviations: GDS = Global deficit score. 
 
4.3.3.2 Predictors	  of	  poor	  outcome	  in	  TBM	  patients	  
Both TBM-IRIS and a higher BMRC severity grading were postulated to 
predict a worse cognitive outcome. Results are shown in Table 4.19. 
 
Table 4.19: GDS classification for TBM patients, stratified by TBM-IRIS status and BMRC severity 
grading 
 GDS impaired p-Value 























Abbreviations: BMRC = British medical research council; GDS = Global deficit score; TBM = 
Tuberculous menigitis; IRIS = Immune reconstitution inflammatory syndrome. 
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Five patients developed TBM-IRIS. Four patients developed IRIS within the 
first 2 months while the other patient presented approximately 11 weeks after 
TBM diagnosis. Although not statistically significant, it is interesting to note 
that 60% of patients with TBM-IRIS were impaired by the GDS while only 20% 
of patients without TBM-IRIS were impaired. The patient with the second most 
impaired cognition (as reflected in a GDS of 2.5) across the entire cohort had 
an IRIS phenomenon. The median GDS score for the TBM-IRIS patients was 
0.5 (SD 1.02). This is in contrast to the median GDS score for the non-TBM-
IRIS patients of 0 (SD 0.85).  
 
The proportion of patients with an impaired GDS was identical for both BMRC 
severity grades. However, if one analyses the BMRC grading against the 
outcomes of GDS classification and death, there is an almost significant 
difference (p=0.059) between patients with a higher BMRC grading and GDS 
classification or death. All of the TBM patient deaths occurred in patients with 
a BMRC grading of 2 while all of the patients with a BMRC grading of 1 
survived.  
 
4.3.3.3 Predictors	  of	  poor	  outcome	  in	  extra-­‐CNS	  TB	  patients	  
We postulated that patients with disseminated TB would perform worse on 
cognitive testing by the GDS compared to patients with single-site TB. 
 
Two patients (14.3%) were impaired by the GDS in the single-site TB group 
compared with two patients (16.7%) in the disseminated TB group (p-value 
1.00). There was also no difference between groups when looking at GDS 
classification or death. 
 
4.3.4 Quality of life and employment status 
4.3.4.1 Quality	  of	  life	  
We postulated that patients with TBM would have poorer QOL as measured 
by the Q-LES-Q-SF (61). This questionnaire has a range from 16-80 with 
higher scores indicating a better quality of life.  
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The median QOL score for TBM patients was 64 (IQR 56-70) with a range 
from 27 to 77. The median QOL score for extra-CNS TB patients was 66 (IQR 
55-74) with a range from 35 to 79. The box-and-whiskers plots illustrate these 
descriptive statistics for the two groups in Figure 4.39.  
 
 
Figure 4.39: Box and whiskers plot of quality of life scores amongst TBM and extra-CNS TB 
patients 
The boundaries of the box are Tukey’s hinges. The median is identified by a line inside the box. 
The length of the box is the interquartile range (IQR) computed from Tukey’s hinges. Values 
more than 1.5 IQR’s but less than 3 IQR’s from the end of the box are labeled as outliers (o).  
Abbreviations: Extra-CNS TB = Tuberculosis outside of the central nervous system; TBM = 
Tuberculous menigitis. 
 
The statistical test of a relationship between TBM and quality of life rendered 
a non-significant p-value of 0.565. 
 
From Figure 4.39 one can see that two patients in the TBM group had outlying 
low QOL scores of 27 and 31. It is interesting to note that these two patients 
had the two highest GDS scores (2.625 and 2.5 respectively) of the entire 
cohort. When one looks at the extra-CNS TB group, the lowest QOL score is 
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35. This patient had a GDS of 1.5, which is the second lowest GDS for the 
extra-CNS TB group and the fourth lowest GDS score overall. This would 
suggest that patients who perform very poorly on cognitive tests may have a 
poorer quality of life. Based on this trend, we investigated whether there was 
an association between QOL and cognitive performance. This scatterplot is 
shown in Figure 4.40. 
 
 
Figure 4.40: Scatterplot of quality of life against the GDS  
GDS = Global deficit score. 
 
As seen from the scatterplot in Figure 4.40, only four patients had a GDS of 
greater than one. Of these four patients, three had the lowest three QOL 
scores. However, the other patient with a GDS of 2.375 had a good QOL 
score of 75. To test the association between QOL and GDS, a Spearman’s 
rho test was performed. This did not support an association (p-value = 0.859) 
with a very weak correlation coefficient of -0.029. 
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4.3.4.2 Employment	  status	  
We hypothesised that a greater proportion of patients in the TBM group would 
lose employment compared to extra-CNS TB patients. Employment status 
data is tabulated in Table 4.20. 
 
Table 4.20: Employment status stratified by TBM exposure 

































Abbreviations: Extra-CNS TB = Tuberculosis outside of the central nervous system; TBM = 
Tuberculous menigitis. 
 
For analysis, we looked at the proportion of patients who lost employment 
over the six-month period following TB diagnosis (see Table 4.20). Note that 
patients were classified as “no loss of employment” if they remained 
employed or if they were not employed at enrollment to start with. Or 
conversely seen, patients were classified as “loss of employment” only if they 
were employed at enrollment and subsequently lost their job in the intervening 
six months before follow-up.  
 
Six (40%) patients with TBM lost employment over the six-month period 
following TB diagnosis compared with seven (26.9%) patients in the extra-
CNS TB group. The difference was not statistically significant (p-value 0.492). 
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Chapter 5: Discussion 
 
5.1 Characteristics of the study population 
The two groups of patients in this cohort study were well matched with no 
significant differences in factors (other than their disease status) that may 
impact on cognition. The cohort is characterised by young to middle aged 
patients from a poor socio-economic background with advanced 
immunosuppression (median CD4 lymphocyte counts below 100 cells/µL for 
both groups) and the majority were not on ART at the time of enrollment.  
 
Both patient groups were exposed to HIV, to the same TB treatment regime 
(although this would extend for a longer period in TBM patients, at the six-
month follow-up timepoint treatment duration was equivalent) and to ART. All 
patients were on ART at the time of cognitive testing, albeit for different 
lengths of time. For the patients who were not on ART at diagnosis, this was 
instated between two and six weeks after the TB diagnosis for the vast 
majority of patients.  
 
In the TBM group, there was a trend to a higher CD4 lymphocyte count and 
longer duration of ART for those patients who were on ART at time of 
enrollment. About a third of patients in the TBM group were on ART at 
diagnosis compared to about half of the extra-CNS TB patients. The 
difference in CD4 lymphocyte count is partly explained by the fact that the 
TBM patients who died had a median CD4 lymphocyte count of 46 cells/µL 
(IQR 35-75) compared with a median lymphocyte count of 103 cells/µL (IQR 
61-170) in the patients who survived. This contrasts with a CD4 lymphocyte 
count in the extra-CNS TB group that was similar for patients who survived or 
died.  
 
Neither group was extensively worked up for other potential causes of 
cognitive impairment, but it is noteworthy that none of the patients who did 
have tests for Vitamin B12 deficiency (n=21), thyroid dysfunction (n=12) 
and/or neurosyphilis (n=19) had abnormal or positive results. Screening for 
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Hepatitis C infection was infrequently undertaken although it has been 
reported to contribute to cognitive impairment (52). 
 
A higher proportion of patients died in the TBM group (37%) than in the extra-
CNS TB group (21%). The mortality rate in the TBM group is slightly lower 
than previous reports of 48% mortality at six months after diagnosis in the 
same province (3). There are a few possible reasons for this. Firstly, early 
deaths in patients with severe TBM may have been missed as our study 
enrolled patients up to 10 days after presentation. Secondly, the original study 
was performed in 2009 compared to ours during 2014-2015: practice in ART 
initiation changed during this time with treatment being started at higher CD4 
lymphocyte counts (<350 cells/µL) compared with CD4 lymphocyte counts of 
<200 cells/µL (101). This may have contributed to better outcomes.  
 
The neurobevioural features of apathy and depression were assessed by the 
AES and BDI-II respectively. These neurobehavioural features are both 
reported to be more common in HIV-infected patients and to impact on 
functioning (102). There was a trend for a higher proportion of patients in the 
TBM group than the extra-CNS TB group to have clinically significant apathy, 
as defined by a score of ≥ 34 on the AES-i (p-value 0.12). This is important as 
this lack of drive/self-initiation impacts not only on cognitive and instrumental 
functioning, but also interpersonal relationships. In our TBM cohort, three out 
of five patients with significant apathy had a normal GDS. This has been 
reported in the literature of HIV-infected patients, where apathy was found to 
correlate with white matter changes even in the absence of cognitive 
impairment or depression (93). On the other hand, apathy has also been 
reported to correlate with executive dysfunction and a common frontal-
subcortical process has been suggested, thereby impacting both on executive 
and neuropsychiatric functioning (103). The rates of moderate to severe 




There was a near-significant difference (p-value 0.06) between the mRS 
scores for the two groups. The more frequent motor disability in TBM patients 
is not unexpected given the burden of TB on the brain, spinal cord and 
lumbosacral roots, in our cohort of TBM patients. 
 
5.2 Primary aim 
Our primary aim was to assess cognitive outcomes in the TBM patient group 
compared to the extra-CNS TB patient group. Our hypothesis was that the 
TBM group would perform worse.  
 
The extra-CNS TB patients had a median GDS of 0 (IQR 0-0.125) whereas 
the TBM group had the same median score of 0 but an IQR of 0-0.5, thereby 
extending into the impaired range.  
 
As measured by the binary GDS, there was a greater proportion of impaired 
patients in the TBM group (33%) compared to the extra-CNS TB group (15%). 
This clinically significant difference did not, however, reach statistical 
significance (p-value 0.248). The most likely reason for this is the small 
sample size, which was not adequately powered to detect a significant 
difference.  
 
Another potential reason for the non-significance of this difference is that 
some patients who were classified as having extra-CNS TB, may have also 
had TBM. Care was taken to avoid this misclassification as a careful search 
for symptoms and signs of TBM was performed, but this clinical method is not 
infallible. Mild disorientation may incorrectly have been ascribed to delirium. 
However, in patients with mild disorientation to the date, this resolved rapidly 
following treatment of the underlying cause (e.g. correction of electrolyte 
disturbance, treatment of urinary tract infection) and was therefore unlikely to 
be due to TBM. Not all patients had a lumbar puncture performed and even if 
they did, normal CSF findings do not rule out TBM. A normal CSF profile has 
been described in HIV-associated TBM in between 13% to 21% of patients, 
especially in the context of advanced immunosuppression (104-106). 
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However, if one considers a normal CSF profile together with the absence of 
clinical symptoms and signs of TBM, a diagnosis of TBM becomes unlikely.  
 
A further possible explanation for the non-significant difference in cognitive 
outcomes between the two groups is that the frequency or severity of HAND 
may differ between the groups. The known risk factors for the development of 
HAND include lower CD4 lymphocyte count (48), advancing age (34), lower 
levels of education (50), and drug and alcohol abuse (49). In our study, the 
extra-CNS TB patients who came to testing had a lower CD4 lymphocyte 
count, older age and more alcohol use. Although none of these differences 
alone were significant, it may be that cumulatively it impacted on HAND 
frequency or severity in the extra-CNS TB group. This in turn may serve to 
dilute the differences in cognitive performance between groups.  
 
5.3 Secondary aims 
5.3.1 Cognitive outcomes by Frascati criteria  
The Frascati criteria (28) are important cognitive measures, as it incorporates 
functioning and therefore has real life consequences for patients receiving 
such a diagnosis. It has been noted that measurement of functional 
impairment can be complex and influenced by cultural and demographic 
factors (36). For example, in our setting of high unemployment, subtle 
difficulties in executive functioning or memory may go unnoticed when a 
profession does not demand it. In other studies of HAND in South Africa, self-
reported ART adherence rates are also used in defining functional impairment 
(107). Some groups propose more objective assessment of functional 
impairment e.g. the Columbia medication management test or the San Diego 
finances test (108). Such a tool has not yet been validated in South Africa.  
 
With these limitations in mind, our study was designed to be relatively 
sensitive to functional decline by using two patient-reported measures 
(modified-IADL and PAOFI) and a relative/carer account (DECO). A patient 
could be rated as impaired by any or all of these three measures.  
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There were eight patients who were impaired by Frascati criteria: four in each 
group. Of these eight patients, only five had functional impairment (two with 
mild impairment, three with severe impairment). There were no differences 
between the two groups when this classification was used.  
 
It is noteworthy that amongst the 13 patients (32% of the entire cohort) with 
functional impairment, more patients had a normal cognitive performance 
(eight patients, 20%) than patients with impaired cognition (five patients, 
12%). Taken together, we can conclude that although poor insight might lead 
to underestimation of cognitive difficulty, all our patients with severe cognitive 
impairment by Frascati criteria (i.e. ≥ 2 SDs below the mean in two or more 
cognitive domains) did have measurable functional impairment. This may be 
due to the fact that proxy report of functional impairment was also 
incorporated in our study design. The converse was seen in our study: more 
patients had functional impairment in the cognitively normal group than in the 
cognitively impaired group. This may be due to the recognised influence of 
affective disturbances (depression in particular) leading to an overestimation 
of cognitive symptoms (87, 109). On the other hand, it may also mean that the 
cognitive battery we used is not sensitive in detecting subtle cognitive difficulty 
that translates to impaired daily functioning. 
 
5.3.2 Description of cognitive impairment by domains 
The domains that were the most impaired were the same for the two groups:  
information processing speed; attention and working memory; and executive 
functioning. The degree of impairment was worse in the TBM group across all 
three domains. This pattern of neuropsychological impairment is in keeping 
with a frontal-subcortical picture and has been well described in HAND (85). 
There have also been reports of poor learning, subcortical memory 
impairment, and reduced verbal fluency in the context of HIV (46), but these 
were not a prominent finding in our cohort as a whole. These domains were, 
however, frequently impaired in the nine patients who had cognitive 
impairment (see Section 5.3.2.1 below).  
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In summary, these findings support a qualitatively similar pattern in both 
groups, but a quantitatively worse outcome in the TBM group. This may be 
due to more severe or widespread frontal-subcortical involvement in the TBM 
group. One could hypothesise that a combined/dual effect of TBM and HIV on 
subcortical structures could lead to such pathology, albeit via different 
mechanisms. In TBM, this would be expected to be largely due to an arteritis, 
resulting in ischaemia (with or without infarction) in the tubercular zone 
(affecting the caudate, anterior thalamus, and internal capsule) whereas in 
HIV, neurotoxicity in similar striatal and white matter structures has been 
postulated (33). 
It is interesting to note that the most discrepant scores were in the domain of 
visuospatial functioning (p-value 0.176) where the extra-CNS TB group had a 
near-normal mean Z-score of 0.06 (SD 0.98) compared with the TBM group 
Z-score of -0.38 (SD 1.06). When one scrutinises the subtests for this domain, 
it seems plausible that this difference is largely accounted for by the 
difference in CLOX 1 scores. This unprompted clock drawing task taps into a 
wide range of cognitive functions: in addition to visuoperceptual and 
visuoconstructional praxis, executive functioning (planning, organisation, 
inhibition and self-monitoring) is also assessed by this task (72, 110). When 
one takes this into account, we should investigate the CLOX 2 performances 
(copying task) as a more pure test of visuoperception or visuoconstructive 
praxis. There was no difference between the two groups on the CLOX 2 task. 
Furthermore, the difference on the JLOT scores; which is a relatively pure test 
of visuospatial functioning; was small. One would therefore caution against 
over-interpreting the domain summary score as an indicator of visuospatial 
skill when it may be reflecting executive dysfunction. However, in the context 
of reports of visuospatial impairment in TBM (15, 16), this is an area that 
warrants further discussion.  
 
Studies in chronic TBM patients have demonstrated impairment in the index 
of perceptual organisation (significantly impaired performance on block design 
and picture completion tests) in a DTI study (16) and a voxel based 
morphometry study (15). Visuospatial impairment has not been widely 
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described in HIV when one compares it with the multitude of reports of frontal 
subcortical involvement (46). However, there has been a MRI cortical 
thickness mapping study in HIV-infected adults demonstrating thinning of the 
parietal cortex (111). The parietal and prefrontal thinning correlated with motor 
and cognitive impairment. A study investigating the relation of numerical and 
spatial cognition in asymptomatic HIV-infected individuals has been reported 
(112). Participants were given tasks of mental number line bisection, physical 
line bisection, and physical number line orientation. The HIV-infected group 
was significantly slower and made more errors on visuospatial and number 
processing tasks than the HIV-uninfected group. These findings were held to 
provide evidence for disruption of frontostriatal circuits and their parietal 
projections. In another DTI study, reduced integrity of the centrum semi-ovale 
was correlated with visuoconstruction and verbal memory impairments (113). 
A study of mental rotation and hierarchical pattern perception in HIV-infected 
men showed impairment in both these visuospatial tasks (114). The authors 
postulated involvement of the inferior parietal cortex to account for these 
visuospatial impairments. But it remains difficult to disentangle the role of the 
frontostriatal structures connected to these cortical areas (46) and further 
studies are needed elucidate the mechanism and neuropathological 
localisation of visuospatial impairment in the context of HIV. 
 
5.3.2.1 Description	  of	  patients	  with	  impaired	  cognition	  
 
The nine patients (five with TBM, four with extra-CNS TB) who had a GDS 
score of ≥ 0.5 were studied in more detail.  
 
The most commonly impaired domain was that of attention and working 
memory (albeit to a mild extent only). The second most commonly affected 
domains were those of learning, memory and verbal fluency. Impaired 
immediate and delayed free recall in the setting of relatively better recognition 
performance was typical.  
 
Qualitatively, a frontal-subcortical picture was seen in all but one patient (who 
had selective impairment of verbal learning and memory). The frontal-
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subcortical picture was not isolated in half of these patients by virtue of 
additional visuospatial impairment. In all four these patients, the impression of 
visuospatial impairment was based on poor performances of the JLOT task as 
well as the copying task of the CLOX 2 (thereby not relying only on the more 
executively loaded CLOX 1 task).  
 
As discussed above in section 5.3.2, the presence of visuospatial impairment 
does not necessarily equate to cortical parietal pathology and may equally be 
due to involvement of frontostriatal pathways connecting to this cortical 
region. The classical division of visuospatial functioning into a ventral (“what”, 
relating to object vision) and dorsal (“where”, relating to spatial vision) stream 
still holds true. But knowledge in this area is expanding and is likely to evolve 
(115). The anatomical pathways have also been elucidated. Initially, the 
ventral stream was described as running through the occipitotemporal cortex 
to its anterior temporal destination, and the dorsal stream as coursing through 
the occipitoparietal cortex to the inferior parietal lobule. It has recently been 
shown that these streams extend further into the prefrontal cortex:  from the 
anterior temporal lobe into the ventrolateral prefrontal cortex for the ventral 
stream; and from the inferior parietal lobe into the dorsolateral prefrontal 






Figure 5.1: Frameworks of visual processing 
From Dwight J. Kravitz, Kadharbatcha S. Saleem, Chris I. Baker, Mortimer Mishkin. “A new 
neural framework for visuospatial processing”. Nat Rev Neurosci. 2011 April ; 12(4): 217–230. 
doi:10.1038/nrn3008. Accessed 12/08/2017.  
Abbreviations: OC = striate cortex, OB = Visual area 2, OA = Visual area 4, PG = inferior parietal 
lobule, TEO = posterior inferior temporal cortex, TE = rostral inferior temporal cortex, FDΔ = 
dorsolateral prefrontal region, FDv = ventral prefrontal region. 
 
The JLOT, used in our battery, has been shown to be a good test of the 
dorsal (“where”) stream. A study using a MRI lesion-deficit mapping technique 
found that impairment on the JLOT was most strongly associated with 
damage to the right posterior parietal region (116). In our patients, we can 
infer pathology either in this region or along the white matter pathways that 
connect this area with the dorsolateral prefrontal cortex (115). Taking into 
account the circumstantial evidence of other frontal-subcortical involvement in 
our patients and the absence of isolated visuospatial impairment, the latter 
would seem the more likely explanation in our affected patients.  
 
Impaired action fluency compared to semantic fluency has been reported in 
patients with HAND (117, 118). This may be due to the fact that the action 
fluency task taps into frontal systems, executive functioning, and motor 
planning. This is contrasted with semantic (category) fluency, which relies 
primarily on temporo-parietal networks and semantic memory stores (119). 
When looking at the nine impaired patients in our cohort, they did not bear out 
this discrepancy. In fact, there were more patients with impaired semantic 
Figure 1. Frameworks of visuospatial processing
a | The original formulation1,2,3 of the dorsal and ventral streams in the macaque monkey.
The ventral stream is a multisynaptic pathway projecting from the striate cortex (area OC) to
area TE in the inferior temporal cortex, with a further projection from area TE to ventral
prefrontal region FDv. The dorsal stream is a multisynaptic pathway projecting from striate
cortex to area PG in the inferior parietal lobule, with a further projection from area PG to
dorsolateral prefrontal region FDΔ. On the basis of the effects of lesions in monkeys, the
ventral stream was termed a ‘What’ pathway supporting object vision, whereas the dorsal
stream was labelled a ‘Where’ pathway supporting spatial vision. b | The top panel depicts
the location of the lesions in patient D.F. (shown in blue and indicated by white arrows) that
led to impairment in object perception but not in the accuracy of orienting her hand when
reaching to the same objects. This pattern of results led to the proposal8,90, depicted in the
bottom panel, that the dorsal stream is more accurately characterized as a motoric ‘How’
pathway supporting visually guided action than as a perceptual ‘Where’ pathway. c | The
new neural framework for dorsal stream function that is proposed in this Review. At least
three distinct pathways emanate from the posterior parietal cortex. One pathway targets the
prefrontal cortex (shown by a dashed green arrow; see also part a) and supports spatial
working memory (the parieto–prefrontal pathway); a second pathway targets the premotor
cortex (shown by a dashed red arrow) and supports visually-guided actions (the parieto–
premotor pathway); and the third targets the medial temporal lobe, both directly and through
the posterior cingulate and retrosplenial areas (shown by a dashed blue arrow), and supports
navigation (the parieto–medial temporal pathway). PCC, posterior cingulate cortex; RSC,
retrosplenial cortex; TE, rostral inferior temporal cortex; TEO, posterior inferior temporal
cortex; V1, visual area 1 (also known as primary visual cortex). Part b, top panel is
modified, with permission, from REF. 5 © (2003) Oxford Journals.
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fluency compared to action fluency. This may be due to the heterogenous 
nature of our cohort with TBM causing involvement of more diverse 
subcortical structures or perhaps more temporal cortical involvement.  
 
5.3.3 Predictors of poor cognitive outcome 
5.3.3.1 Predictors	  of	  poor	  cognitive	  outcome	  in	  both	  groups 
None of the factors investigated showed a significant association with 
cognitive outcomes. There was a weak trend however for older age and ART 
duration of less than 200 days to associate with poor cognitive outcomes as 
measured by a GDS of ≥ 0.5. These findings are in keeping with published 
literature. Older age is recognised to associate with worse cognitive 
performance in studies of HAND (34). A systematic review of the effect of 
ART on neurocognition has been conducted by Joska et al. (57) and they 
found that ART does improve cognitive functioning in HIV-infected individuals, 
although it does not cause complete resolution of impairments.  
 
Looking at cognitive outcomes and deaths, there was a weak trend for a 
positive association between a CD4 lymphocyte count of less than 60 cells/µL 
and this combined outcome. This finding of an association between advanced 
immunosuppression and death is not surprising. 
 
5.3.3.2 Predictors	  of	  poor	  cognitive	  outcome	  in	  TBM	  group	  
Although not reaching statistical significance, the presence of TBM-IRIS was 
associated with cognitive impairment in 60% of patients contrasting with 
cognitive impairment in only 20% of non-TBM-IRIS patients. This finding has 
clinical significance, as the risk of cognitive impairment may be higher in the 
context of TBM-IRIS as opposed to TBM without an IRIS phenomenon. This 
gives further impetus to ongoing studies on ways to prevent TBM-IRIS in high-
risk patients. 
 
There was no association between BMRC disease severity grading and GDS 
classification. However, there was a near-significant association between 
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BMRC grading and GDS classification or death, with all patient deaths 
occurring in patients with a Grade 2 classification. This is consistent with 
reports of poorer outcomes in patients with higher BMRC disease severity 
grades (120, 121). 
 
5.3.3.3 Predictors	  of	  poor	  cognitive	  outcome	  in	  extra-­‐CNS	  TB	  group	  
There was no difference in cognitive outcomes between patients with single-
site TB or disseminated TB. A potential confounder is the fact that treating 
physicians may not pursue an extensive search for TB in other sites once it 
has been proven in one (e.g. after receiving a positive sputum result for TB, 
abdominal ultrasound may not be deemed necessary as it would not change 
treatment in that particular patient). Therefore, it is possible that a proportion 
of patients with single-site TB in fact did have undocumented disseminated 
TB. 
 
5.3.4 Quality of life and employment status 
5.3.4.1 Quality	  of	  life	  
There was no significant difference between the QOL scores for the two 
patient groups. It was interesting to note that the patients with the three lowest 
QOL scores all had significant cognitive impairment (their scores were 
amongst the four lowest scores overall). There was no association overall 
though for QOL and GDS, suggesting that this association of poor QOL with 
cognitive impairment apply to the outlying patients only.  
 
5.3.4.2 Employment	  status	  
There was no significant difference between the loss of employment rates for 
the two patient groups. The relatively small number of patients who were 
employed at enrollment (about half of the TBM group, about 60% of the extra-
CNS TB group) is likely to contribute to weak power to detect a significant 
difference. It is disconcerting that 40% of TBM patients and 27% of extra-CNS 
TB patients lost their job in the six months following their TB diagnosis. 
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5.4 Strenghts and limitations 
 
5.4.1 Strenghts 
As far as we know, this is the first study of cognitive outcomes in HIV-infected 
adult patients with TBM. The two study groups were well matched in terms of 
CD4 lymphocyte count, exposure to ART, and TB treatment duration. This 
was a cohort of vulnerable patients with advanced immunosuppression from a 
poor socio-economic background. The cognitive battery was detailed, 
spanning eight cognitive domains, and included measures of visuospatial 
functioning (which is not routinely included in tests of HAND). Cognitive tests 
were always administered in the patients’ first language with the aid of an 
isiXhosa translator. All the cognitive tests were administered by the 
investigator herself, which ensured continuity and limited the confounding 
effects of inter-rater variability. It also gave her a qualitative impression of 
cognitive performance and features that may impact on performance (e.g. 
lack of motivation, poor concentration, anxiety). This was a highly enjoyable 
aspect of the study, and patients overall perceived it as a positive experience 
too. The use of a locally derived normative sample (n=114) for cognitive tests 
is a further strength of the study. This data will also be useful for future 
cognitive studies in this population. The measurement of functional 
impairment was assessed in detail (both patient and proxy reports of 
functioning were taken into account) and this helps to translate findings of 
cognitive impairment into real life meaning for the study participants. 
Additionally, neurobehavioural features of depression and apathy were 
assessed as important potential confounders of cognitive performance. 
 
5.4.2 Limitations 
Our study had several limitations. The most important limitation is the small 
sample size and this is the most likely reason for the non-significance of the 
between-group differences. The first reason for the small sample size is 
limited resources (manpower, study duration, and costs involved) as well as a 
high loss to follow-up rate in the extra-CNS TB patient group. Reasons for the 
loss to follow-up included patients relocating to other provinces (in most 
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instances these were patients who returned to their province of birth following 
their illness), patients declining further participation (mostly applicable to 
working patients who were hesitant to lose a day of employment), and 
patients not having a fixed dwelling and/or contact number or losing a mobile 
phone if they had one. Unconfirmed death is also a possibility, although this 
could account for loss to follow-up of four patients only. The disproportionate 
loss to follow-up in the extra-CNS TB group creates a potential bias for 
cognitive outcomes.  
 
The next limitation is the presence of a major risk factor (HIV) for the outcome 
of interest (cognitive impairment) in both patient groups. However, an HIV and 
TB co-infected control group was chosen for two reasons:  Firstly, the burden 
of HIV and TB co-infection in South Africa is large and devastating and 
therefore warrants description. In theory, by having HIV present in both 
cohorts the additional effect of TBM on cognition could still be analysed. 
Furthermore, if one were to compare HIV-infected adults with TBM with 
patients with HIV only, there would be more between-group differences than 
these imposed by our study design: differential TB drug effects on the CNS; 
chronic inflammation due to TB, with chronic inflammation having been shown 
to affect neurodegeneration (122, 123); and degree of immunosuppression; all 
of these would have been likely confounders. Secondly, although a third 
control group consisting of HIV-uninfected adults with TBM was considered, 
only 12% of adult TBM cases are HIV-uninfected in our setting (3) and it 
would have been difficult to recruit an adequate number of patients to 
generate sufficient statistical power.  
 
A challenge in the design of our study is that the presence of TBM in patients 
assigned to the non-exposed (extra-CNS TB) group cannot be ruled out 
altogether. We relied on the absence of clinical symptoms and signs of TBM 
(4), but this is not infallible. A retrospective study of HIV-infected adults with 
TBM from Brazil found that only 15% of patients presented with the classical 
triad of fever, headache, and meningeal signs simultaneously (105). On the 
other hand, a large prospective comparison study in Vietnam by Thwaites et 
al. (54) looked at the influence of HIV infection on clinical presentation of TBM 
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in adults. They did not find significant differences between how HIV-infected 
and HIV uninfected patients presented. In our study, it may be that subtle 
confusion due to TBM may have been incorrectly judged to be due to delirium, 
of which there are many potential causes in this setting (e.g. hyponatremia, 
hypoxia, sepsis, drug effects). Arguing against this is the fact that the few 
patients who had mild disorientation to the date, all improved rapidly following 
correction of the underlying cause of delirium. To further complicate this 
matter, the presence of a normal CSF profile does not rule out TBM, 
especially in patients with low CD4 lymphocyte counts (124) and it has been 
shown that patients with HIV infection are more likely to present with normal 
protein or an acellular CSF (106). We did keep these limitations in mind, and 
took care to minimise the misclassification of TB patients as far as possible. 
 
Our study was observational in nature, and therefore neuroimaging was not 
routinely performed in this cohort of patients. In fact, the secondary level 
hospital from which most patients were recruited, does not have a CT scanner 
on site. Patients have to be referred to a tertiary level hospital for this, which 
brings about its own logistical challenges and makes clinicians reluctant to 
request this test unless there is a strong clinical indication. We were therefore 
unable to draw any for clinico-radiological conclusions.  
 
The follow-up time point for cognitive testing was chosen to be six months, as 
this allowed a similar duration of exposure to TB drugs for both groups 
(treatment would be extended to nine months in total for TBM patients, whilst 
for most extra-CNS TB patients, treatment would be stopped after six 
months). This is important, as the anti-tuberculous drug, Isoniazid, is known to 
be a potential cause of CNS toxicity (125) and can lead to psychosis, seizures 
or encephalopathy (126). One could argue that the six-month time point was 
too early and that a full treatment course for TBM should have been 
completed prior to cognitive testing. However, testing patients at different time 
points such as at completion of TB treatment (six months for extra-CNS TB 
patients and nine months for TBM patients), or at nine months in both groups, 
would both have introduced its own confounders. From a HAND point of view, 
there may have been a benefit in extending the follow-up period, as some 
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patients were only started on ART after enrollment (usually two to six weeks 
after TB treatment was initiated). This means that these patients would have 
been on ART for shorter than six months at the time of cognitive testing. In a 
review of studies of the effectiveness of ART on neurocognitive function (57), 
the duration of ART use ranged from 8 weeks to 2 years, but most studies 
employed an average study period of 6 months. It has been shown that 
clinically meaningful neuropsychological improvement peaks around six to 
nine after ART was initiated (127). However, our two patient groups did not 
show significant differences in terms of duration of ART at follow-up, so the 
inadequate effects of ART would be similar across groups.  
 
We did not exclude patients who drank alcohol, but instead used the AUDIT 
scale to assist in stratifying use. Patients with high level drinking or 
dependence in the preceding six months, as defined by the AUDIT score ≥ 
16, were excluded. Alcohol use is a potential confounder of cognitive 
impairment and one could argue that a more stringent cut-off could have been 
used. However, there was no significant difference in alcohol use between 
groups. Furthermore, when stratifying patients with an AUDIT score ≥ 8, there 
was still no significant difference between groups. Due to resource 
constraints, we did not perform urine toxicology screening on our patients, but 
relied instead on self-report of substance use. This is a limitation as patients 






Chapter 6: Conclusion and recommendations 
 
To our knowledge, this is the first study of cognitive outcomes in HIV-infected 
adults with TBM. It adds value to the description of patients with HIV and TB 
co-infection, which is a common and devastating scenario in South Africa. 
Although limited by small numbers and our inability to reveal statistically 
significant differences between groups, there were trends towards more 
frequent and more severe cognitive impairment in patients with TBM 
compared to patients with extra-CNS TB, at six months after TB diagnosis.  
 
The majority of cognitively impaired TBM patients had TBM-IRIS.  
 
The neuropsychological picture was similar between groups, supportive of a 
frontal-subcortical process, and characterised by slowed information 
processing speed; impaired attention and working memory; and executive 
dysfunction. Additionally, there was a non-significant trend towards more 
visuospatial impairment in the TBM group.  
 
Future studies in TBM patients with HIV infection are needed to confirm 
whether this trend towards more cognitive impairment in TBM patients is 
borne out. The design of future studies should include a larger sample size 
and may include a third control group of HIV-uninfected patients with TBM. 
The addition of neuroimaging at diagnosis or shortly thereafter would aid in 
elucidating clinico-radiological associations. Furthermore, the follow-up period 
for cognitive testing may be extended to two time points: at six and 12 
months, thereby allowing for completion of TBM treatment and for optimal 
effect of ART to take place. The cognitive battery may include more detailed 
visuospatial testing and tests of language, in addition to the domains tested in 
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